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ABSTRACT 
Lyme disease (LD) is a tick-borne infection caused by Borrelia burgdorferi (Bb) that has 
a global impact and a high incidence in the United States. If not treated with antibiotics 
during the early stages of the disease within the first few weeks of infection, patients 
usually develop musculoskeletal symptoms and neurological complications that can 
include neurocognitive and neuropsychiatric manifestations. For many, regardless of the 
stage of the disease or duration of the infection, antibiotic treatment with oral or 
intravenous antibiotics is curative. Nevertheless, up to 20% of individuals that receive 
antibiotic treatment during late-stage infection do not find relief from their symptoms, 
despite multiple rounds of antibiotic therapy. Collectively, the symptoms that persist 
after antibiotic treatment are called Refractory Lyme arthritis (RLA) when symptoms are 
predominantly rheumatologic, or post-treatment Lyme Disease syndrome (PTLDS) 
when symptoms are predominantly neurologic, neuropsychiatric and/or neurocognitive. 
Neither of the syndromes is mutually exclusive. Currently there is no FDA approved 
treatment for PTLDS, and although autoimmune etiologies have been proposed, a 
definitive causal mechanism has not been identified.   
 
A major limitation in our understanding of neurologic LD and its associated syndrome 
PTLDS is the lack of a suitable mouse model for modeling neurologic Bb infection. In 
section 1, we provide background on LD and summarize the hypotheses and approaches 
that we took in our research. In section 2, we review T cell and dendritic cell 
contributions to inflammation in RLA, to underscore what is known about complications 
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of LD. Section 2 closes with a brief discussion of PTLDS and neuroborreliosis, to 
emphasize the questions that are currently understudied in LD. In section 3, we present a 
novel mouse model of neuroborreliosis that results from Bb infection of C3H/HeN mice, 
using the North American CSF-tropic strain of Bb, Bb 297, and an intradermal route of 
inoculation. We demonstrate that intradermal infection with Bb 297 results in persistent 
infection of the meninges and the brain, that CD4+ T cells accumulate in the brain 
during early and late-stage LD, and that both persistent infection and neuroimmune 
changes are temporally associated with significant behavioral deficits in nociception, 
mobility, and movement. In section 4 we provide a discussion of the implications of the 
research that we have performed. 
   
 
iv 
 
DEDICATION 
 
This dissertation is dedicated to my wife, Debra, who patiently and fully supported my 
dream to obtain my doctorate; to my hardworking immigrant parents, Divan Fard and 
Simin Pouya, who taught me that no dream is unattainable; to my two children, Faith 
Aria Divan and Caleb Cyrus Divan, who always gave me something to be happy about 
when I came home from long hours in the laboratory; to my pastor, Louis Best, who 
helped advise me when I had to make tough personal decisions; and to the thousands of 
individuals that suffer from complications of Lyme Disease, yet have not received the 
cure they have been praying and hoping to receive. 
 
 
   
 
v 
 
ACKNOWLEDGEMENTS 
 
I would like to thank my outstanding mentor, Dr. Karen Newell-Rogers for her 
encouragement, optimism, and willingness to take big risks on my wild ideas. I will 
forever be grateful for the opportunity that she gave me to work with her and to learn so 
much from her. I would also like to thank my committee members, Dr. David Zawieja, 
Dr. Cynthia Meininger, and Dr. Xu Peng, for guiding me through the scientific method 
and providing me with the constructive criticism that I needed to learn how to think like 
a scientist. I would also like to thank Dr. Jon Skare for teaching me the methodology for 
culturing Borrelia burgdorferi, and for generously continuing to support my work with 
culture reagents from his laboratory. Thank you to Dr. Lee Shapiro and Dr. Damir 
Nizamutdinova for helping me design behavioral studies, and thank you to Dr. Sanjib 
Mukherjee and Dr. Richard Tobin for teaching me many of the laboratory techniques 
that I utilized to perform this dissertation project. Thank you to Mr. Anand Narayanand 
for working closely with me to design experiments for immunostaining.  
 
Thank you to the charitable organizations that funded my research in Lyme Disease, 
specifically the Global Lyme Alliance and Mr. Rob Kobre. 
   
 
vi 
 
CONTRIBUTORS AND FUNDING SOURCES 
 
Contributors 
This work was supervised by a dissertation committee consisting of Dr. Karen-Newell 
Rogers [advisor, Department of Surgery], Dr. David Zawieja [co-advisor, Department 
Head, Department of Medical Physiology], Dr. Cynthia Meininger [committee member, 
Department of Medical Physiology], and Dr. Xu Peng [committee member, Department 
of Medical Physiology].   
 
Dr. Karen Newell-Rogers contributed to experimental design, data analysis and 
interpretation of data, and helped write/edit all manuscripts. Dr. Ralph Budd and Dr. 
Richard Tobin assisted with writing the manuscript presented in chapter 2. Dr. David 
Zawieja and Mr. Anand (Sunny) Narayanand contributed to experimental design for 
immunostaining and imaging in the manuscript presented in chapter 3. Dr. Lee Shapiro 
and Dr. Damir Nizamutdinova contributed to experimental design for behavioral tests in 
manuscript presented in chapter 3. Ms. Anna Webb provided instruction and training on 
confocal microscopes that were used for imaging in the manuscript presented in chapter 
3.  Dr. Sanjib Mukherjee contributed to experimental design for tissue harvesting in the 
manuscript presented in chapter 3. Dr. Jon Skare provided instruction on culture 
methodology of Borrelia burgdorferi and provided the medium for Borrelia burgdorferi 
culture. Ms. Jessica Kain provided technical support with mouse colony management.  
 
   
 
vii 
 
Funding Sources 
This work was supported by the Global Lyme Alliance, the Texas A&M University 
Health Science Center, and the Baylor Scott & White Foundation.  
 
 
   
 
viii 
 
TABLE OF CONTENTS 
 Page 
ABSTRACT ...................................................................................................................... II 
DEDICATION .................................................................................................................IV 
ACKNOWLEDGEMENTS .............................................................................................. V 
CONTRIBUTORS AND FUNDING SOURCES ............................................................VI 
TABLE OF CONTENTS .............................................................................................. VIII 
LIST OF FIGURES ........................................................................................................... X 
LIST OF TABLES ...........................................................................................................XI 
1. INTRODUCTION .......................................................................................................... 1 
1.1 The Current State of Lyme Disease ......................................................................... 1 
1.2 Clinical Signs and Symptoms .................................................................................. 3 
1.3 Post-infectious Complications ................................................................................. 5 
1.4 Coinfections ............................................................................................................. 6 
1.5 Diagnosis and Treatment .......................................................................................... 7 
1.6 Animal Hosts and Experimental Animal Models .................................................. 11 
1.7 CSF, Brain Glymphatics and Meningeal Lymphatics ............................................ 20 
1.8 Major Gap in Knowledge ....................................................................................... 22 
1.9 Research Overview ................................................................................................ 24 
1.9.1 Central Hypothesis .......................................................................................... 24 
1.9.2 Background ..................................................................................................... 24 
1.9.3 Approach ......................................................................................................... 25 
1.9.4 Aim 1 ............................................................................................................... 26 
1.9.5 Aim 2 ............................................................................................................... 31 
1.9.6 Aim 3 ............................................................................................................... 32 
1.9.7 Significance ..................................................................................................... 38 
2. GAMMA DELTA T CELLS AND DENDRITIC CELLS IN REFRACTORY 
LYME ARTHRITIS ......................................................................................................... 39 
2.1 Synopsis ................................................................................................................. 39 
2.2 Introduction ............................................................................................................ 39 
2.3 γδ T Cells in Inflammatory and Infectious Diseases .............................................. 42 
2.4 Characterization of γδ T cells in Lyme Arthritis .................................................... 43 
2.5 γδ T cells and the Dendritic Cell ............................................................................ 44 
   
 
ix 
 
2.6 Fas:FasL Signaling in Murine Lyme Polyarthritis Models .................................... 45 
2.7 γδ T Cell Activation Depends on TLR2 in Lyme Disease ..................................... 49 
2.8 Non-classical Antigen Presentation in Lyme Disease and RLA ............................ 51 
2.9 The Reciprocal Roles of Caspases ......................................................................... 55 
2.10 IL-17 in RLA ........................................................................................................ 57 
2.11 γδ T Cells in the Transition Between Innate and Adaptive, Specific Immunity .. 59 
2.12 Concluding Remarks on RLA .............................................................................. 61 
2.13 Understudied Complications of LD ..................................................................... 62 
3. EVIDENCE FOR LONG-TERM PERSISTENCE OF BORRELIA 
BURGDORFERI IN THE MENINGES .......................................................................... 65 
3.1 Synopsis ................................................................................................................. 65 
3.2 Introduction ............................................................................................................ 66 
3.3 Methods .................................................................................................................. 67 
Animals. ................................................................................................................... 67 
Bb culture and infection. .......................................................................................... 68 
Tissue harvest and tissue culture. ............................................................................. 68 
Immunostaining. ....................................................................................................... 69 
Leukocyte isolation and flow cytometry. ................................................................. 70 
Von Frey pain test. ................................................................................................... 71 
OF test. ..................................................................................................................... 72 
NORT Test. .............................................................................................................. 72 
Statistical analysis. ................................................................................................... 73 
Data availability. ...................................................................................................... 73 
3.4 Results .................................................................................................................... 74 
3.4.1 Dura Supports Bb Growth During Late-stage Infection ................................. 74 
3.4.2 Bb Localizes to Blood Vessels in the Dura ..................................................... 76 
3.4.3 Elevated CD4+ T cells in the Brain During Early and Late-stage Infection ... 83 
3.4.4 IgG Detected in Brain During Late-stage Infection ........................................ 85 
3.4.5 Behavioral Deficits During Late-stage Infection ............................................ 91 
3.5 Discussion .............................................................................................................. 93 
4. SUMMARY ................................................................................................................. 97 
4.1 LD and its Post-infectious Complications .............................................................. 97 
4.2 Persistent Bb Infection in the Dura and Brain........................................................ 99 
4.3 Neuroimmunology of LD ..................................................................................... 107 
4.4 Altered Behavior .................................................................................................. 111 
4.5 Limitations of This Study ..................................................................................... 114 
4.6 Concluding Thoughts and Future Directions ....................................................... 118 
5. REFERENCES ........................................................................................................... 123 
   
 
x 
 
LIST OF FIGURES 
 Page 
Figure 1.1  Enzootic Life Cycle of Bb ........................................................................ 13 
Figure 2.1  Fas:FasL interactions ................................................................................ 47 
Figure 2.2  OspA activates dendritic cells via TLR engagement ............................... 54 
Figure 2.3  Cell signaling between γδ T cells and DCs during Bb infection .............. 64 
Figure 3.1  Borrelia persistence in dura 45 dpi. .......................................................... 81 
Figure 3.2  Bb is culturable from 45 dpi dura and persists in association with 
blood vascular endothelium ..................................................................... 82 
Figure 3.3  Infection by Bb does not alter BBB integrity. .......................................... 84 
Figure 3.4  Flow cytometric gating strategy for B cells in the dura and brain. .......... 88 
Figure 3.5  Flow cytometric gating strategy for T cells in the dura and brain. .......... 89 
Figure 3.6  B2 B cells and CD4+ T cells in brain and dura. ....................................... 90 
Figure 3.7  IgG deposition in the brain and ventricles during late-stage Bb 
infection. ................................................................................................... 92 
Figure 3.8  Behavioral changes in Bb-infected mice 45 dpi. ...................................... 95 
Figure 3.9  Schematic diagram of OF testing and NORT. ......................................... 96 
 
   
 
xi 
 
LIST OF TABLES 
 Page 
 
Table 1.1  Transmission kinetics. ................................................................................ 4 
Table 1.2  Aim 1. ....................................................................................................... 29 
Table 1.3  Aim 2 ........................................................................................................ 34 
Table 1.4  Flow cytometric approach ........................................................................ 35 
Table 1.5  Proposed behavioral testing ..................................................................... 36 
Table 3.1  Tissue culture ........................................................................................... 77 
Table 3.2  Brain culture ............................................................................................. 78 
Table 3.3  Dura culture .............................................................................................. 79 
Table 3.4  DCLN culture ........................................................................................... 80 
Table 3.5  Gating strategy ......................................................................................... 87 
Table 4.1  Additional behavioral tests ..................................................................... 122 
 
 
 
 
  
   
 
1 
 
1. INTRODUCTION  
 
1.1 The Current State of Lyme Disease 
Lyme disease (LD) is a zoonotic bacterial infection caused by a variety of borrelia-
species spirochetes including B.burgdorferi, B.hermsii, B.miyamotoi, B.afzelli, B.garinii, 
and B.bissettii (1-4). Collectively, these pathogenic species of Borrelia are called 
Borrelia burgdorferi sensu lato (Bbsl), meaning the broad sense of Borrelia burgdorferi. 
Bbsl occurs globally, has been reported in many countries, and it is most prevalent in 
North America and Europe (5).  Epidemiologic and ecologic data provides evidence that 
Bbsl can infect a variety of vertebrate hosts including multiple species of rodents, birds, 
rabbits, and deer (5). In North America the most commonly observed species of Borrelia 
is Borrelia burgdorferi sensu stricto (Hereon referred to as Bb), meaning the strict sense 
of Borrelia burgdorferi, and it is especially prevalent in white-tailed deer and white-
footed mice (5). Although Bb is the most prevalent and well-studied species of borrelia 
in North America, it is not the only borrelia species that exists, as evidence demonstrates 
that B.hermsii, B.miyamotoi, and the newly-discovered species B.mayonii are found in 
both animals and humans in the United States (1, 6, 7).  
 
In the United States, Bb infection in humans was first observed in the 1970s among 
children presenting with polyarthritis, within three distinct communities in eastern 
Connecticut (8-11). At the time it was not known whether the cause of infection was 
viral or bacterial, but investigative efforts among physicians and researchers 
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demonstrated that a spirochetal bacterium was the causative agent of the disease (9-11). 
Later it was determined that the transmission of Bb depended on a vector that could 
harbor the infection from feeding on an infected host, and transmit it to another host, 
without itself succumbing to the pathological effects of the infection. Thus far, evidence 
has only supported Bb and Bbsl disease transmission to occur through the bite of a tick 
that carries the organism (9, 12). Hard-bodied ticks belonging to the family Ixodidae 
transmit Bb in North America, and Bbsl in Europe (13-15), and although it is unknown 
whether soft-bodied ticks of the family Argisidae can transmit Bb, it is well-established 
that soft-bodied ticks can transmit some of the Borrelia infections belonging to the Bbsl 
group, including B.hermsii (1). In rodent studies, evidence suggests that an infected tick 
will transmit Bb to a host 93% of the time if the tick remains attached for 72 hours (16). 
In humans, it is not known what the minimum time requirement is for a tick to transmit 
Bb to a host, but infection has been shown to occur commonly in human patients ~24 
hours after attachment (17), and as early as 4 hours after attachment (18). Multiple 
factors can affect the kinetics of disease transmission between the tick and the host, and 
these factors include 1) bacterial burden and physical distribution of infection in the tick, 
2) feeding behaviors of the tick, 3) species of host, 4) species of Borrelia, 5) species of 
tick 6) life cycle of the tick, and 7) presence of other co-infections, as summarized in 
Table 1.1(19). Overall, there remains much to be investigated regarding the tick as a 
vector for LD and associated borrelioses.      
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1.2 Clinical Signs and Symptoms 
The pathognomonic clinical sign of LD is an erythema migran (EM) skin lesion that 
usually manifests during the early stages of the disease at the site of the tick bite, within 
the first 7-14 days after infection (20). The lesion begins as a small rash that expands in 
diameter, leaving an alternating ring of clearance that makes the rash resemble a 
bullseye. Besides changes in the appearance of the skin, an EM is asymptomatic, does 
not cause pain or itching, and as a result it may be overlooked, especially if it occurs in a 
location that the patient may not see, such as the back (21). Importantly, not all patients 
will develop EM, and the absence of EM does not rule out LD. Typically the EM clears 
within a matter of days to weeks, and during this time an overlap of acute LD symptoms 
begin to manifest in the musculoskeletal system, the cardiovascular system, and if left 
untreated, the nervous system (20, 22).  
 
Musculoskeletal symptoms are the most commonly reported symptoms, and they include 
myalgias and arthralgias that are migratory and are typically accompanied by fever, and 
fatigue. Carditis is a sign of early disseminated LD, and it occurs in 1-4% of infected 
individuals, presenting as electrophysiological conduction disturbances, most often in 
the atrioventricular AV node (23).  Men in their 20’s – 40’s have the highest risk for 
developing Lyme carditis, with a preponderance of men outweighing women by a factor 
of at least 3:1 (24). In rare cases, spontaneous cardiac arrest due to Lyme carditis has 
been reported (25). During the early stages of infection (1-4weeks), antibiotic treatment 
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Table 1.1 Transmission kinetics. Effects of different variables on the transmission time of Borrelia infections 
between ticks and vertebrate hosts 
 
Species of Host
B.afzelli < B.burgdorferiSpecies of Borrelia B.burgdorferi (ss), B.afzelli, 
Bb infection in midgut, 
salivary gland, hemolymph, or 
systemic
Bacterial Burden/location Systemic infection and salivary gland 
infection < hemolymph < midgut
Feeding behavior Questing duration, prior 
partial feeding
Long questing duration and/or prior 
partial feeding < short questing duration 
and no prior partial feeding
Variable Example Transmission time*
Table 1.1 Transmission kinetics. Effects of different variables on the transmission time of borrelia infections between ticks and 
vertebrate hosts
*Data are presented in descending order, showing the variable that corresponding to the fastest transmission time first, followed by 
variables that require longer tick attachment times to transmit borrelia infections
I.scapularis, I.persulcatus, 
I.ricinus
I.ricinus and/or I.persulcatus < I.scapularisSpecies of Tick
Adult or nymph
Tick co-infected by 
A.phagocytophylum, 
E.chaffensis, B.hensalae, 
B.microti
Co-infection
Life Cycle of tick Effect on transmission rate not reported
Effect on transmission rate not reported
Rodent, Human Human < Rodent
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with doxycycline is generally well-tolerated and most patients recover from the infection 
without complication. If clinical diagnosis is delayed, neurological symptoms may 
develop/worsen. The earliest that neurological symptoms have been reported is 14 days 
after infection, but they can occur as late as months after infection (23, 24). Neurological 
symptoms can include seventh cranial nerve palsy, meningitis, sensory or motor 
radiculopathies, encephalomyelitis or axonal polyneuropathy (25).  Cognitive 
abnormalities are often reported by patients, and neuropsychiatric disorders can also 
occur, ranging from depression, mania, psychosis, and dementia (26).  Cognitive 
abnormalities usually include difficulty with verbal fluency, short-term memory, and 
processing speed (often referred to as “brain fog”), and evidence from functional 
imaging studies suggests that these abnormalities are associated with encephalopathy, 
impaired blood flow, and altered metabolism in the brain (23, 27, 28).   
 
1.3 Post-infectious Complications 
In addition to increasing the risk of neurological symptoms, delayed treatment can also 
increase the risk of long-term or permanent disability subsequent to antibiotic treatment. 
When antibiotic treatment has been given, but neurological and/or neurocognitive 
symptoms persist beyond 6 months after therapy, the resulting combination of symptoms 
is called post-treatment Lyme disease syndrome (PTLDS) (29). It is estimated that up to 
20% of individuals that have neurological symptoms go on to develop PTLDS, despite 
antibiotic therapy. Importantly, there is a difference between untreated LD, and PTLDS. 
In untreated LD, neurocognitive symptoms are accompanied by objective physical 
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findings such as recurring EM rashes, cranial nerve palsy, meningitis, or radiculitis (29). 
In PTLDS, the clinical spectrum usually excludes objective physical findings, although 
significant neurocognitive abnormalities in processing, fatigue, and widespread 
musculoskeletal pain persist (29).  At this time there is no FDA approved treatment for 
PTLDS, and although the topic remains controversial, prolonged antibiotic therapy has 
not been shown to be beneficial (29). Another distinct manifestation of LD is Antibiotic-
Refractory Lyme arthritis (RLA), and it is characterized by arthritic symptoms that 
persist subsequent to antibiotic treatment, in the absence of neurological sequelae (29, 
30). RLA has an association with the DRB4 and DRB2 alleles of the DRB human 
leukocyte antigen (HLA-DRB), suggesting that antigen presentation and/or 
autoimmunity may underscore the development of RLA (30). Gamma delta T cells (γδ 
T) are also evidenced to play an important role in the development of RLA(31). 
 
1.4 Coinfections  
Acute or untreated LD can often be complicated by other co-infections that are 
transmitted via the bite of a tick at the same time as B.b transmission. Examples of tick 
borne coinfections include Ehrlichia, Anaplasma, Babesia, and Bartonella, and the 
prevalence of each co-infection depends heavily on the geographic setting (32). In the 
United States, the overall prevalence of B.burgdorferi and at least one other co-infection 
in ticks ranges from 9.4%-26% (33-35). Given the similarities between co-infection rates 
and the prevalence of PTLDS, it is tempting to speculate that co-infection may play a 
role in the development of PTLDS, or other post-treatment complications of LD. 
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Consistent with the possibility that coinfection facilitates PTLDS, Babesia microti, a 
protozoan parasite, has been shown to increase disease severity and duration of LD when 
transmitted as a co-infection with Bb (34, 36).  There is also evidence that Anaplasma 
phagocytophilum co-infection with Bb increases production of multiple matrix 
metalloproteases and the cytokines IL-6, TNF-α, IL-10, and IL-8, resulting in increased 
permeability of brain microvascular endothelial cells in vitro (37).  Ehrlichia chaffensis 
is capable of establishing central nervous system (CNS) infection, and thus when 
transmitted as a co-infection, it may provide permissive conditions for Bb to enter the 
CNS (38). Although tick-borne transmission of Bartonella species may be possible, 
Bartonella has not yet been demonstrated to be a major contributor to tick-borne 
coinfection in the human population. Collectively, the relatively high prevalence of co-
infections suggests that studying Bb infection in isolation may not represent the full 
spectrum of LD that occurs in patient populations. Thus, in both research and clinical 
settings, it may be especially important to consider co-infections in LD, particularly as 
they relate to host-mediated physiological responses and parallel immune responses that 
may determine disease outcomes, including the development of post-treatment sequelae 
such as PTLDS.   
 
1.5 Diagnosis and Treatment 
The diagnosis of LD is most accurately made based on clinical the presentation of 
symptoms, and history of a tick bite (39). For individuals that are in Lyme endemic 
areas, a timely diagnosis is more likely, due to public health efforts to educate both 
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patients and physicians on LD signs and symptoms. The presentation of an EM at the 
time of a clinical visit is sufficient objective evidence that justifies antibiotic therapy 
(40). In the acute phase of the disease, 21 days of treatment with doxycycline (100mg 
twice per day) is the preferred therapy, because it is reported to be effective in the 
treatment of LD, human granulocytic anaplasmosis (HGA), human granulocytic 
ehrlichiosis (HGE), and human monocytic ehrlichiosis (HME) three coinfections that are 
caused by Anaplasma and Ehrlichia bacterial species (40, 41). Rifampin therapy has also 
shown efficacy in the treatment of HGA and HME (42). In cases where EM cannot be 
distinguished from community-acquired cellulitis (CAC), the Infectious Disease Society 
of America (IDSA) guidelines recommend antibiotic treatment with cefuroxime axetil or 
amoxicillin-clavulanic acid, as both of these antibiotics are reported to have activity 
against LD and CAC (40).  If at the time of clinical presentation, coinfection by Babesia 
is suspected, either due to signs/symptoms or prevalence of the parasite in the 
geographical area, babesial parasites can be detected by blood smear, or by polymerase 
chain reaction (PCR) assay. The recommended treatment for babesiosis and LD is 7-10 
days of combination therapy with either ativaquone and azithromycin, or in severe cases, 
intravenous clindamycin, quinine, and blood transfusion. In individuals with persistent 
symptoms of babesiosis, a longer duration of therapy may be considered (40).   
 
Up to 20% of patients may not present with EM during the acute phase of LD, and for 
these patients, diagnosis may not occur until after the onset of arthritis or neurologic 
involvement (39, 40). Because many of the secondary and tertiary symptoms of LD can 
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resemble other diseases such as multiple sclerosis, amyotropic lateral sclerosis, and 
systemic lupus erythematosus, serology is usually necessary in the differential diagnosis 
(40, 43). The current Centers for Disease Control (CDC) recommended serology is a 
two-tiered approach consisting first of an enzyme-linked immunosorbent assay (ELISA), 
and if positive, followed by a western blot (WB) test. If an ELISA is positive, and the 
patient has been infected for < 30 days, then 2/8 IgM bands or 5/10 IgG bands must be 
positive on the WB for a positive LD diagnosis. If ELISA is positive, and the patient has 
been infected for ≥30 days, then only positive IgG bands (5/10) should be used to 
interpret the test result. A negative ELISA is recommended as exclusion criteria for LD.  
 
The ELISA assay works by detecting host-derived IgM or IgG antibodies that are 
reactive against whole Borrelia proteins, derived from sonicated Borrelia cells. In the 
acute phase of the disease, ELISA may not be useful because seroconversion does not 
occur this early for all individuals. Consequently, up to 50% of individuals that are 
infected may produce negative ELISA results during the acute phase of the disease, 
although convalescent serology may improve sensitivity up to 80% (44, 45). 
Interestingly, the duration of EM positively correlates with ELISA sensitivity. For 
example, in patients that have had EM for a duration of <7 days ELISA sensitivity is 
13% (44). It is unknown how sensitive ELISA may be for infected individuals that do 
not present with EM. During the secondary and tertiary stages of the disease, IgG ELISA 
sensitivity is reported to be as high as 89%, however the values can vary substantially 
between different test manufacturers, because even FDA-approved ELISA tests for LD 
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have not been standardized against panels of well-characterized sera from patients (44, 
46, 47). Because, antibodies against other antigens can occasionally cross-react with 
sonicated Bb proteins, the specificity of ELISA is relatively lower than its sensitivity, 
generally about 70% (47). Thus, for surveillance purposes a positive ELISA may not 
definitively indicate LD, and for this reason, WB is recommended as a secondary 
confirmation test.  
 
The WB assay uses immunodominant Bb antigens of known molecular weights to detect 
reactive antibodies in sera. Much like ELISA, WB is not a useful tool for detecting LD 
during early infection, however, for surveillance purposes it is a useful test to confirm 
LD infection when ELISA is positive (44). Overall, WB testing has sensitivity of 
approximately 85% (44). Generally, most WB tests use antigens derived from the B31 
strain of Bb, and although useful, the focus on this particular strain may exclude antigens 
that would result in a positive diagnosis of individuals that are infected by other strains 
of Bb, such as strain 297, N40, or other Bbsl species such as B.miyamotoi, or B.hermsii 
(44). In contrast to the ELISA, a positive WB is highly specific for LD infection, with 
specificity reported as high as 95% (44).  
 
The two-tiered CDC criteria that requires a positive ELISA, followed by a positive WB, 
increases the specificity of the LD test to 99%, with a respective sensitivity of 87% (44, 
48). High specificity provides excellent guidelines for surveillance cases. From the 
perspective of research, it is most favorable to err on the side of specificity, rather than 
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sensitivity, because specificity ensures that positive samples are truly positive. In 
contrast, these criteria may not be ideal for a clinical setting. In the clinical setting it is 
not always possible to determine the exact disease, and in some cases it is most 
equitable/cost efficient to determine the most probable disease(s). Based on 
consideration for patients, and the low risk associated with oral-antibiotics in the 
treatment of LD, it seems more logical to err on the side of caution for the patient, and to 
prescribe antibiotic treatment if LD is a possibility. Based on the CDC criteria, up to 
13% of patients that have LD will return negative serology, and may receive inaccurate 
diagnoses. This unfavorable outcome underscores the need for higher sensitivity testing 
that keeps specificity in an acceptable range. In the near future, multiplex platforms may 
provide a method for ELISA-based assays to test for seroreactivity to multiple Bbsl 
strains and species, thus potentially improving sensitivity and/or specificity.  
  
 
1.6 Animal Hosts and Experimental Animal Models 
Bbsl and Bb are prevalent in the wild, especially among birds, rabbits, and rodents (5). 
In north America, the most common animal reservoir for Bb is Peromyscus leucopus, the 
white-footed mouse. The white-footed mouse is an efficient host for Bb infection 
because it is readily accessible to ticks (especially larval and nymphal ticks), acquires Bb 
infection rapidly, but does not experience any selective disadvantage from acquiring 
infection (49, 50). With respect to infection efficiency, it is estimated that greater than 
90% of white-footed mice that are bitten by a Bb-infected tick, become permanently 
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infected with Bb. Thus, a single feeding session by an infected tick can result in Bb 
transmission to the white-footed mouse, and the white-footed mouse can then transmit 
Bb to multiple ticks for the duration of its life. Deer, including white-tailed and mule 
deer, are important hosts for the maintenance of Bb-infected adult ticks, but contrary to 
popular belief, deer are not competent host reservoirs for LD, as they appear to clear Bb 
infection spontaneously. Therefore, the prototypical lifecycle of LD is characterized by 
infection of larval/nymphal ticks by a Bb infected white-footed mouse, followed by 
maturation of the tick into an adult that will either remain persistently infected while 
feeding on deer, or will remain persistently infected and transmit the infection to a dead-
end host, such as a human or dog (5, 51) (Figure 1.1).  
 
LD is also observed in livestock, making LD a relevant concern in large animal 
veterinary medicine. Evidence suggests that cattle are susceptible to LD due to a variety 
of Bbsl species, but infection of cattle by Bb is not supported in the literature (52, 53). 
Horses are also susceptible to LD due to Bbsl, although in contrast to cattle, evidence 
suggests that Bb can also establish infection and produce pathology in horses (54-56). 
Among domestic animals, dogs are the most common species infected by Bb, and much 
of the clinical presentation revolves around polyarthritis (57, 58). Although there are 
sporadic veterinary reports of neurological symptoms in dogs infected by Bb, CNS 
infection or involvement is not supported in studies using experimental infection (59). 
This does not rule out the possibility that dogs may be susceptible to CNS pathology 
during or subsequent to Bb infection under different circumstances. Interestingly, cats do
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Figure 1. 1 Enzootic Life Cycle of Bb. Larval  ticks feed on Bb-infected rodents, 
resulting in transmission of Bb to larva. Infected larva mature into nymphs and continue 
to feed on rodents resulting in new transmission of Bb to uninfected ticks and hosts.  
Infected adult ticks feed on Bb-resistant deer and lay uninfected eggs. Transmission of 
Bb to “dead end” targets, such as humans, can occur through the bites of infected nymph 
or adult ticks.  
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produce measurable serologic responses to Bb infection, but they do not typically 
succumb to any apparent pathologies. Some have hypothesized that in contrast to dogs, 
cats may produce a sufficient innate immune response that prevents the infection from 
disseminating (57, 58). As a zoonotic disease, LD is relevant in many different animal 
species, providing many potential options for experimental animal models. 
 
Experimental infection of animals in the laboratory has produced important advances in 
our understanding of the mechanisms that Bb utilizes to establish infection. Thus far, the 
animal species have that have aided in understanding Bb pathophysiology are dogs, non-
human primates (NHP), rats, and mice. Dogs were among the first species to provide 
evidence that Bb transmission by the tick vector may produce a unique 
microenvironment that facilitates a different course of disease than infection by needle 
inoculation of culture-grown bacteria (60). Subsequent studies have revealed that 
experimentally infected dogs remain culture positive and PCR positive for Bb after 
antibiotic treatment with doxycycline or amoxicillin, despite resolution of arthritis and 
negative serology after antibiotic treatment (61). Dogs have also been a good model for 
understanding histopathological changes in inflamed tissues due to Bb infection (62). 
Interestingly, even in sub-clinical cases, histopathological changes consistent with 
synovitis are evident. Finally, dogs have proven useful models for evaluating the 
efficacy of outer surface protein A (OspA) based vaccines, demonstrating that 
vaccination with OspA provides significant protection from Bb infection (63-65). Unlike 
humans, evidence does not support CNS involvement during Bb infection in dogs, and 
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dogs produce a measurable response to OspF that does not appear to occur in humans 
(59, 66). The last two observations indicate that although dogs are a useful laboratory 
model for understanding pathological changes in joints during Bb infection, the course 
of their immune responses might not faithfully replicate human immune responses to Bb, 
and mechanisms underlying CNS pathology in humans are unlikely to be elucidated by 
canine laboratory experiments.  
 
The NHP model of LD replicates human Bb infection more closely than in any other 
species, presumably due to the overwhelming similarity (>95%) in the genetic 
composition between NHPs and humans (67). Notably, and in contrast to other species, 
Rhesus macaques (RM), a type of NHP, develop EM in the acute phase of Bb infection, 
and some investigators speculate that the immune response that contributes to EM 
formation conditions the Bb spirochete for disseminated infection (67). The brain 
structure of the RM closely resembles the relative size and morphology of a human 
brain, the exception being the number of folds in the brain. Comparatively, there is 
almost no morphological difference between the brain of a 6kg infant, and a 6kg RM 
(67). Like humans, RMs also develop chronic Bb infection if left untreated, and 
immunosuppression by corticosteroids exacerbates disease dissemination and tissue 
pathology, especially in the meninges of the spinal cord (68). Generally, when 
neuropathology occurs in RMs, it is associated with inflammation of the meninges, 
spinal nerve roots, and the dorsal root ganglion. In immunocompetent animals, 
inflammation is typically associated with intrathecal antibody production in the 
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cerebrospinal fluid (CSF), and PCR or culture positivity of tissues in the CNS (69). 
Consistent with increased intrathecal antibody production, the B cell attracting 
chemokine CXCL13 is also elevated in the CSF (70). Histopathological evidence reveals 
that Bb is typically observed attached to the meninges, nerve roots, or ganglia of the 
spinal cord, but not in the parenchyma of the spinal cord (68, 71).  Overall, the NHP 
model is most appropriate for understanding neurological manifestations of human LD, 
due to the similarities in genetic composition between hosts, and in disease 
progression/pathology. The primary obstacles to using NHPs are the husbandry costs 
and the time associated with conducting such research. Unlike other laboratory animals, 
RMs take years to reach sexual maturity. The female reaches sexual maturity at 3 years 
of age, whereas the male is sexually mature at 4 years of age. When fertilization occurs, 
gestation time takes 164 days, and the interval between births ranges between 12 and 24 
months. Thus, it can take as long as 8.5 years for two RM infants to produce a sexually 
mature F1 generation. Breeding strategies can be employed that take advantage of social 
dynamics within breeding groups to expedite the interval range between births, and after 
females reach sexual maturity, they remain sexually viable for up to 20 years. Despite 
the utility of the existing breeding strategies, the high cost of producing and maintaining 
NHPs makes them unsuitable for early investigations, or investigations that require high 
n values to model LD.  
 
Rats are not typical reservoirs for LD in the wild, however, epidemiological studies in 
the United States and in Norway have revealed that rats are competent hosts for Bb and 
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Bbsl in urban settings (72, 73). Consistent with these observations, investigators have 
successfully used rats as experimental models for LD to study routes of infection 
transmission, and communicability of LD in utero and with respect to contact 
transmission between littermates (74). These early studies contributed to the current 
experimental models of LD by demonstrating that intradermal inoculation closely 
resembles a tick bite, and that LD is not communicable by physical or sexual contact, 
nor does the infection appear to be transmitted in utero. Sprague-Dawley rats have been 
used to reliably recapitulate polyarticular arthritis and to model neuroinflammation via 
microglial activation, although direct infection of the CNS is not supported in rats (75, 
76). Rats were also among the first experimental models to reveal that Bb undergoes 
significant antigenic changes in the host’s immune environment, as compared to when it 
is cultured in vitro, suggesting that a host-adapted spirochete may resemble tick-borne 
infection more accurately than culture grown Bb (77). Indeed, current studies in mice 
have corroborated the pathological similarities between tick-borne infection, and 
infection with host-adapted spirochetes (78). Overall, the rat has been demonstrated to 
be a useful experimental model for LD, however, as is discussed below, the laboratory 
mouse has even more utility than the rat, and is therefore the most widely used animal 
model for LD.  
 
Although the rat model of LD preceded the mouse model, the development of transgenic 
mice provided incentive for investigators to identify suitable mouse models for LD, thus 
allowing them to use transgenic mice to study gene function (79-82). The decision to 
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switch to mouse models was further supported by observations that white-footed mice 
are natural reservoirs of LD in the wild (83, 84). Investigators identified three mouse 
strains that were useful for modeling different manifestations of LD, and many of those 
models currently remain in use (79). C3H/HeJ or C3H/HeN mice infected intradermally 
before 12 weeks of age develop severe polyarthritis, whereas Balb/c mice manifest 
cardiac symptoms of LD faithfully, characterized by conduction disturbances resulting in 
carditis (79, 85). Unlike the other two strains, C57/BL6 mice do not develop arthritis or 
carditis in response to Bb infection, but they do develop significant lymphoadenopathy, 
characterized by germinal center dysfunction and immature B cell proliferation in lymph 
nodes near the site of infection (78, 86, 87). Similar to human infection, untreated LD 
results in persistent infection in all three strains of laboratory mice (88). Remarkably, 
serum from human patients infected by Bb provides substantial protection against Bb 
infection in C3H/HeJ mice, suggesting that there is likely overlap in epitopes presented 
between humans and mice (89). 
 
Another advantage of mice as experimental models for LD is that different inbred strains 
have different major histocompatibility complex (MHC) alleles that correspond to 
human HLA alleles, thus allowing investigators to determine whether there are factors 
related to antigen presentation that may contribute to disease severity or susceptibility. 
Although not yet studied in LD, the recent development of the human immune system 
mouse, provides an experimental mouse model that develops human innate and adaptive 
immune cells instead of murine immune cells (90-92). Human immune system mice 
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have been shown to reconstitute 40-60% of human CD45+ mononuclear cells in the 
peripheral blood and in the spleen, with relatively appreciable frequencies of B cells, T 
cells, NK cells, monocytes/macrophages, and DCs (93), suggesting that this model may 
provide a suitable method for investigating the effects of diseases on the human immune 
system.  
 
Other practical considerations that make the mouse especially suitable for modeling LD 
(and many other diseases) include factors such as the availability/cost of reagents, and 
the cost of husbandry. By far, there are a greater variety of conjugated and unconjugated 
antibodies available for staining mouse tissues or cells, and the overall quantity of these 
reagents that are produced exceed that of any other laboratory animal species. Mice are 
also significantly smaller than rats, and as a result smaller quantities of reagent are 
needed to achieve a particular dosage of treatment. For example, a 1mg/kg dosage of 
lipopolysaccharide (LPS) for a 30g adult mouse would require 30µg of reagent. The 
same treatment administered to a 300g adult rat would require 300µg of LPS, a ten-fold 
increase in the quantity of reagent per treatment group. The smaller size of mice also 
requires relatively less space, and less food, thereby reducing overall costs for care and 
husbandry. Overall, an appropriate mouse model of neurological LD would greatly 
contribute to our understanding of pathophysiological mechanisms that may underlie 
neurological LD, and its associated complications that occur in patients. Below, we 
discuss recent discoveries in neuroimmunology and neuroanatomy that are potentially 
relevant to neurologic LD.  
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1.7 CSF, Brain Glymphatics and Meningeal Lymphatics 
The primary region where CSF is produced is the choroid plexus (CP), anatomically 
located in the 3rd ventricle of the brain. Unlike the tight-junction connected capillaries of 
the blood brain barrier (BBB), the capillaries that vascularize the CP are semi-
permeable, and interstitial fluids can exit the capillary beds with relatively little 
resistance (94). Despite the relative permeability of the CP capillary beds, interstitial 
fluids cannot easily escape the perivascular spaces surrounding the CP, because the 
epithelial layer of the CP is lined by tight-junction connected ependymal cells that 
regulate which molecules are transported into the ventricles of the brain. Thus, similar to 
the BBB, the blood-CSF barrier is tightly regulated(94).  
 
Ependymal cells facilitate the production of CSF by selectively regulating Na+, HCO3-, 
K+, and Cl-, ions across ion channels and shuttling water via aquaporin-1 or aquaporin-4 
mediated transport(95). The overall contribution of water to the volume of CSF is 
substantial, as it comprises 99% of the volume of CSF, compared to only 92% in blood 
((96). CSF continually bathes the brain, circulating through the 4 ventricles of the brain 
and through the perivascular Virchow-Robin spaces of the brain parenchyma. As CSF 
circulates through the Virchow-Robin spaces, it produces a convective effect that draws 
out interstitial fluids that are produced by blood circulation in the brain (94). Overall, 
CSF functions to continually remove interstitial fluid from the brain, ultimately draining 
it back into the lymph and peripheral blood. The collective term for CSF-mediated 
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transport of interstitial fluid inside the brain is called the glymphatic system, based on its 
similarity to the peripheral lymphatic system (97).  
   
The glymphatic and lymphatic systems working together recycle and renew CNS 4-12 
times per 24 hour period (94). There are three proposed models that explain CNS 
recycling. The first, and oldest model demonstrates that CSF exists the CNS through 
small fingerlike projections that protrude from the subarachnoid spaces of the spinal 
cord, called arachnoid villi. The arachnoid villi penetrate through the dura and into 
neighboring venous plexi, that drain the contents back into the blood and/or lymph (98). 
The second model shows that the contents of CSF can also drain through the 
subarachnoid space proximal to the olfactory bulb of the brain. Near the olfactory bulb, 
CSF flows behind the cribiform plate, and drains into the lymphatic vessels of the nasal 
mucosa that connect to the superficial and deep cervical lymph nodes (99, 100). The 
third, and most recent model, demonstrates that lymphatic vessels are present in the 
dura(101). Each meningeal lymphatic network appears to start from both eyes and runs 
above the olfactory bulb before connecting to the dural sinuses. The dural sinuses run 
parallel to the superior and transverse sagittal sinuses, and evidence suggests that these 
vessels transport T cells and some portion of CSF from the dura into the deep cervical 
lymph nodes (101). All three models of CNS fluid dynamics are supported by evidence, 
however, the mechanisms underlying immune surveillance and immune trafficking to 
and from the brain, especially in the context of infection, remained incompletely 
understood.  
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1.8 Major Gap in Knowledge 
Overall, the incidence of LD that is caused by Bb in the United States is estimated to be 
approximately 300,000 per year (102). Recent investigations also reveal that other 
Borrelia species belonging to Bbsl are emerging in the United States, suggesting that the 
total incidence of LD caused by all Bbsl species would likely exceed the 300,000 
estimate (1, 6, 7). Most individuals that are infected by Bb recover if diagnosed and 
treated promptly, but not all individuals develop the pathognomonic sign of an EM, 
while others do develop EM, but do not notice it due to its location on the body (i.e. 
scalp or back) (39, 40). Those that do not receive timely diagnosis may go on to develop 
secondary or tertiary symptoms that include polyarthritis, polyneuritis, encephalitis and 
carditis (40). Neurological symptoms are associated with a higher risk of developing 
PTLDS, a debilitating syndrome that up to 20% of individuals with neurological 
manifestations of Bb develop, despite antibiotic treatment (43). At this time there are no 
FDA approved treatments for PTLDS, and physicians are limited in the types of 
approaches that they can use for PTLDS patient management (29). 
 
A key factor that limits our understanding of neuroborreliosis and its potential 
complications such at PTLDS is the lack of a high efficiency and cost-effective animal 
model that faithfully replicates human manifestations of neurological LD. The RM is an 
accurate model for human neuroborreliosis, but the high cost of care, long reproduction 
time, and small litter size make it unfeasible for early investigations or approaches that 
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require large sample sizes. Thus far, the laboratory mouse has been instrumental in 
understanding the pathological features of LD that relate to arthritis and carditis, as well 
as the mechanisms that Bb utilizes to subvert immune detection and to persist in an 
otherwise immunocompetent host (31, 78, 79, 85-88, 103-109). Although some 
investigators have attempted to develop a mouse model of neuroborreliosis, the 
inoculation route of Bb was intracerebroventricular, and thus it did not model the true 
course of infection, which is intradermal (110). The recent discovery of the meningeal 
lymphatics also highlights the importance that tissues within the CNS, especially the 
meninges, may have in regulating immunity, and understanding the role that these 
tissues play during LD may elucidate underlying pathophysiological mechanisms of LD.   
Thus, there is a major gap in our understanding of neuroborreliosis, and this is due in 
part to the lack of a suitable mouse model. Minimally, a mouse model that could 
replicate Bb infection, and/or Bb-induced inflammation in the CNS could provide an 
avenue to understand the course of the disease in humans, including the post-treatment 
complications such as PTLDS. Below, we propose a novel experimental approach, using 
the Lyme arthritis susceptible C3H/HeN mouse as a potential model for 
neuroborreliosis.   
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1.9 Research Overview 
1.9.1 Central Hypothesis  
Bb infection establishes persistent infection in brain-associated meninges, resulting in 
neuroimmunological changes and behavioral deficits 
 
1.9.2 Background 
LD is one of the fastest growing infectious diseases in the United States.  Of the patients 
that acquire LD, up to 20% may develop chronic symptoms, in spite of antibiotic 
treatment, a condition known as PTLDS (29). Why some individuals do not recover 
from LD infection remains unknown, although the possibilities include 1) persistent 
infection in the CNS or associated tissues, 2) post-infectious autoimmunity that results in 
neuropathology, and/or 3) permanent damage to the CNS. The long-term effects of Bb 
infection on the brain and its associated tissues are not well understood, and relatively 
little is known about the neurological consequence of long-term Bb infection in mice. 
Typically, neurological Bb infection has been modelled in NHPs, and although the NHP 
model is useful for modelling the disease, its major limitation is the high cost of primates 
and their maintenance. In the work presented below, we sought to produce a mouse 
model of late-stage neurological Bb infection, using the LD susceptible C3H/HeN mice, 
a common American strain of Bb (Bb 297), and intradermal inoculation as the route of 
infection.   
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1.9.3 Approach 
Although many strains of mice including C57BL6, Balb/c, and C3H are susceptible to 
infection with Bb, the C3H/HeN strain is an especially good model for cardiomyopathy 
and acute inflammation of the joints (88). In most mice, the highest susceptibility to Bb 
infection occurs at ~6-8 weeks of age (79, 88). Intradermal needle inoculation of Bb 
spirochetes has been established as a physiologically relevant method for modeling tick 
transmission of Bb (85), as it results in acute infection (within 3-5 days of inoculation), 
and disseminated infection that occurs within weeks. Similar to the course of LD in 
humans, in the absence of antibiotic treatment, Bb infection persists in most mice (88). 
 
There are three strains of Bb that are commonly used to model experimental infection in 
the United States, strains B31, N40, and 297. Bb 297 is a particularly appropriate strain 
for modeling neurological infection because it is currently common in the human 
population in the United States, and this strain has been shown to result in infection of 
the CSF, suggesting that it has some tropism for tissues associated with the CNS (111). 
In patients, neurological infection can begin as early as 3 weeks after infection, and 
typically manifests within 6-12 weeks after tick-transmitted Bb infection (20). 
Accordingly, we infected mice with Bb 297, and we evaluated the presence of 
neurologic infection, changes in neuroimmune phenotypes, and behavior, early in 
disease and during late-stage disease, where neurologic infection was expected, 
corresponding to 5 days post infection (dpi), and 45 dpi, respectively.  
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In C3H/HeN mice, it has been demonstrated that Bb inoculum is typically most effective 
for transmitting chronic infection when the initial inoculum dose is transmitted 
intradermally and contains 104-106 spirochetes (88). Importantly, when Bb spirochetes 
are cultured in vitro for the purpose of experimental infection, they must be kept at low 
passage number (usually <20 passages), otherwise the spirochetes become adapted to in 
vitro conditions and they lose their virulence factors and the ability to produce 
experimental infection (112, 113). Furthermore, experimental infections require that the 
spirochetes are in the mid-log phase of growth, because this is the phase of growth 
where protein expression has the least variation between Bb spirochetes within the same 
culture (113). 
 
1.9.4 Aim 1 
Aim 1: Determine if intradermal infection with Bb 297 results in infection of brain or 
dura 
Rationale: Bb 297 is a strain that was originally isolated from the CSF of a patient in 
New York (111). Because Bb 297 has tropism for the CSF, and the CSF is a fluid that 
encapsulates the brain, and circulates through perivascular spaces of the brain 
parenchyma (94), we reasoned that 1) spirochetes would be present in CSF of LD 
susceptible C3H/HeN mice, and 2) spirochetes would establish infection in the brain and 
its associated tissues, including the meninges. It has also been established that Bb has 
tropism for decorin, a collagen bound protein, as well as other components of the 
extracellular matrix (114, 115). Importantly, collagen and decorin are expressed in the 
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meninges, and the arterial walls of the blood vessels that supply the meninges (116, 
117). Decorin is also expressed in the gray matter of the developing neocortex, 
hypothalamus, and thalamus (118).   
Hypothesis: Intradermal infection of C3H/HeN mice with Bb 297 will result in infection 
of the brain and meninges within 45 dpi.  
 
1.9.4.1 Aim 1.1 
Aim 1.1: Determine if Bb spirochetes can be cultured from brain or meninges of Bb 
infected mice, early in infection (5 dpi), and late in infection (45 dpi).   
Rationale: BSK-II medium is routinely used to culture Bb spirochetes in vitro until the 
concentration of spirochetes is sufficient for use in experimental infection. Many 
investigators have also used BSK-II medium to culture Bb out of the tissues of Bb-
infected mice (88, 103).  
Experimental design: For each experiment, we infected male, C3H/HeN mice that were 
6-8 weeks old at the time of infection, with 106 low passage (<6), mid log-phase Bb 297 
spirochetes in BSK-II medium. All injections were given via the intradermal route of 
inoculation in the dorsal thoracic midline. Mice were euthanized at time points of 5 dpi, 
or 45 dpi, to assess whether Bb could persist in the CNS at these time points. Sham 
mice, injected intradermally with BSK-II medium only, were used as negative controls. 
While under anesthesia, each mouse was perfused transcardially to remove all blood, 
followed by the removal and collection of brain and meningeal tissues. Tissues were 
evaluated for evidence of Bb infection by culturing the tissues in BSK II medium for 12 
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days. The number of spirochetes that grew out from the culture was quantified by dark 
field microscopy. Experiments were performed as described in Table 1.2.   
Methods to assess Bb persistence:  
Tissue culture: To determine if any spirochetes remained in the tissues of interest, we 
cultured the extracted tissues in BSK-II medium for up to 12 days. Culturing the 
extracted tissues provided us with insight about whether host-adapted Bb spirochetes in 
our tissues of interest were sufficiently viable or resilient to replicate in culture.
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Table 1.2 Aim 1. Experimental treatment groups for completion of Aim 1.1 and Aim 1.2 
Group 
Number
Treatment ID Description
n per tx 
group
Number 
of 
groups
Tissues 
collected upon 
euthanasia
Methods of 
assessment
Rationale for  each 
treatment
1 5dpi Bb
Mice infected with Bb 297. 
Euthanized after 5 days
5 1
Test borrelia 
persistence after 5 
days of infection
2 5dpi Sham
Mice treated with BSK-II medium. 
Euthanized after 5 days 
5 1
Negative control for 
vehicle after 5 days 
of inoculation
3 45dpi Bb
Mice infected with Bb 297. 
Euthanized after 45 days
5 2
Test borrelia 
persistence after 45 
days of infection
4 45dpi Sham
Mice treated with BSK-II medium. 
Euthanized after 45 days 
5 2
Negative control for 
vehicle after 45 days 
of inoculation
n values were determined based on power analysis using GPower3 software and the following parameters: apriori analysis, difference 
between two independent means, Beta = 0.20, alpha = 0.5, and an effect size of 2.19 that was calculated based on preliminary data (not 
shown)
Total mice needed to address aim = 30
Dura, Brain
 tissue culture (n=5 
for each)
immunostaining, 
tissue culture (n=5 
for each)
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1.9.4.2 Aim 1.2 
Aim 1.2: Determine if spirochetes or spirochete antigens persist in meninges of Bb 
infected mice late in infection (45 dpi).   
Rationale: Although tissue culture is a suitable method for determining whether viable 
bacteria persist in tissues, it does not address whether any bacterial remnants, for 
example antigens, or “viable but nonculturable” Bb spirochetes may persist in tissues 
(103, 119). Furthermore, culture positivity does not provide information about the 
anatomical region in the tissue where persistent infection may occur. Therefore, we 
performed immunostaining followed by confocal imaging to determine whether any 
spirochetes or spirochete remnants remained in the meninges, and if so, where in the 
tissues they localized.     
Experimental design: Mice were infected and euthanized as described in aim 1.1. All 
samples were immunostained for Bb, CD31, and LYVE-1, and they were imaged by 
confocal microscopy. Experimental groups are described in Table 1.2.     
Methods to assess Bb persistence: 
Immunostaining/confocal imaging: After euthanasia, the dura were removed and fixed in 
2% paraformaldehyde overnight, followed by immunostaining. Immunostaining was 
performed for Bb, the blood vessel marker CD31, and the lymphatic vessel marker 
LYVE-1. All staining was performed using primary unconjugated polyclonal IgG 
antibodies, followed by secondary staining with fluorophore conjugated anti IgG. 
Tissues were mounted in DAPI containing mounting medium for the detection of 
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nucleated cells. Samples were imaged on Olympus and Leica confocal microscopes and 
images were processed using ImageJ software.  
 
1.9.5 Aim 2 
Aim 2: Determine if intradermal infection with Bb 297 results in changes in B or T cell 
populations in the brain or meninges 
Rationale: Immune cells in the CNS have been shown to play a role in the etiology of 
neurodegenerative diseases such as Multiple Sclerosis, Alzheimer’s disease, Parkinson’s 
disease, and acute-onset neurological diseases such as Guillain-Barre syndrome (120, 
121). Although, it has not been proven definitively, evidence suggests that post-
infectious complications of LD, such as RLA and PTLDS, may have autoimmune 
etiologies that can involve subsets of B cells and T cells (23, 29, 31, 122). It is possible 
that immune related events that occur in the CNS during neurological LD may set the 
stage for the outcome of the disease, either in favor of disease resolution, or toward 
autoimmunity. Accordingly, we aimed to address whether any changes in B or T 
lymphocytes were detectable in the CNS during early infection (5 dpi), or late-stage 
infection (45 dpi).  
Hypothesis: C3H/HeN mice infected by Bb have measurable differences in B cell and T 
cell immune subsets in the brain and meninges during early (5 dpi), and late-stage (45 
dpi) infection.  
Experimental design: Mice were infected and euthanized as described in Aim 1.1. After 
euthanasia, brains and meninges were removed and put in single cell suspension, stained 
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with fluorochrome conjugated antibodies, and evaluated for immunophenotypic changes 
by flow cytometry. Treatment groups are described in Table 1.3.  
Methods to assess changes in leukocyte populations: 
Isolation of leukocytes: While under anesthesia, each mouse was perfused with 60mL 
Ca++ / Mg++ free, phenol red-free Hank’s balanced salt solution (HBSS). Each head was 
removed and the skullcaps were cut out for the isolation of the dura. Dura were 
incubated in collagenase to dissociate cells from tissue. The resulting suspensions of the 
brains and dura were triturated through a 100um strainer to produce single cell 
suspensions. To remove myelin, brain single cell suspensions were centrifuged over 37% 
Percoll and the myelin-containing top layer was removed by vacuum aspiration.  
Staining and flow cytometry: All cells were stained with 1:100 dilution of fluorochrome-
conjugated monoclonal antibody, as described, in serum block buffer for 20 minutes. 
Stain panels and gating strategies are described in Table 1.4. Samples were washed and 
run on Becton Dickinson (BD) FACS CANTO II flow cytometer, and data was analyzed 
using FlowJo software 
 
1.9.6 Aim 3 
Aim 3: Determine if long-term infection with Bb 297 results in behavioral deficits 
Rationale: Neurological LD and its post-treatment complication, PTLDS, typically take 
several weeks to months to develop (20, 29, 40). In patients that have neurological LD or 
PTLDS, objective sensory/motor and cognitive deficits are often present (23, 29, 123). 
Typical deficits include difficulties with verbal fluency, impaired short-term memory, 
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impaired ability to process information, fatigue, sleep disturbances, peripheral 
neuropathy and depressed mood (23, 123, 124). To date, we have not identified any LD 
behavioral studies performed in any mouse models of LD. Thus, we aimed to determine 
if there were any underlying behavioral deficits in LD-susceptible C3H/HeN mice 
infected by the CSF-tropic strain of Bb, Bb 297.    
Hypothesis: C3H/HeN mice infected intradermally with Bb 297 develop behavioral 
deficits manifesting as increased peripheral nociceptive response, decreased motor 
function, anxiety, and impaired short-term memory.  
Experimental design: Mice were infected as described in Aim 1.1, for 45 dpi only, and 
euthanized. Nociceptive responses were be measured using the Von Frey pain test, as 
described (125). Changes in motor function, and anxiety behaviors were assessed by the 
open field test (OF) (126, 127). Short-term visual memory was assessed by the novel 
object recognition test (NORT) (126, 128). The OF and NORT tests were recorded 
digitally and performed on the same day as described in Table 1.5. OF and NORT video 
data were analyzed using Noldus Ethovision XT12 software. 
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Table 1.3 Aim 2. Experimental treatment groups for completion of Aim 2 
Group 
Number
Treatment ID Description
n per tx 
group
Number 
of 
groups
Tissues 
collected upon 
euthanasia
Methods of 
assessment
Rationale for  each 
treatment
1 5dpi Bb
Mice infected with Bb 297. 
Euthanized after 5 days
5 1
Test changes in 
leukocytes after 5 
days of infection
2 5dpi Sham
Mice treated with BSK-II medium. 
Euthanized after 5 days 
5 1
control for vehicle 
effects after 5 days 
of inoculation
3 45dpi Bb
Mice infected with Bb 297. 
Euthanized after 45 days
5 1
Test changes in 
leukocytes after 45 
days of infection
4 45dpi Sham
Mice treated with BSK-II medium. 
Euthanized after 45 days 
5 1
control for vehicle 
effects after 45 days 
of inoculation
n values were determined based on power analysis using GPower3 software and the following parameters: apriori analysis, difference 
between two independent means, Beta = 0.20, alpha = 0.5, and an effect size of 2.19 that was calculated based on preliminary data (not 
shown)
Total mice needed to address aim = 20
Dura, Brain Flow Cytometry
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Table 1.4 Flow cytometric approach. B cell and T cell antibody panels and flow 
cytometric gating strategy 
Panel
Antibodies in 
Panel
Subset Gating Strategy
Aqua
CD45
CD3
CD19
CD4
CD8
Aqua
CD45
CD3
CD19
CD5
CD1d
IgD B10
Singlet, Aqua-, CD45high, CD3-, 
CD19+, CD5+, CD1d+
Singlet, Aqua-, CD45high, CD3+, 
CD19-, CD4+, CD8-
Singlet, Aqua-, CD45high, CD3+, 
CD19-, CD4-, CD8+
Singlet, Aqua-, CD45high, CD3-, 
CD19+, CD5+, CD1d-
Singlet, Aqua-, CD45high, CD3-, 
CD19+, CD5-, IgDlow
Singlet, Aqua-, CD45high, CD3-, 
CD19+, CD5-, IgDhigh
CD4
CD8
T cell
B1a
B1b
B2
B cell
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Table 1.5 Proposed behavioral testing. Approach and timing for OF and NORT tests.  
Test Phase Duration (min) Subsequent resting interval (min)
Open field Habituation 10 90
Novel object recognition - 1 Learning 5 90
Novel object recognition - 2 Testing 5 N/A
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Methods to assess behavioral changes:  
Von Frey pain test: The Von Frey pain test was performed on an elevated surface with 
small holes in the base. Each mouse was allowed to habituate to the environment for 3 
minutes. The tip of the Von Frey filament was applied to the plantar surface of each hind 
paw. If a withdrawal response did not occur, the next largest filament was used. If a 
withdrawal response was elicited, the next lowest filament was used until no withdrawal 
response occured. The filaments were then increased in size again until a withdrawal 
response occured. This method was repeated until a single filament elicited 4 
consecutive withdrawal responses, indicating the end of one trial. Two trials were 
conducted on each hind-paw of each mouse per treatment group.  
OF test: Each mouse was placed in a 31 cm x 32 cm plexiglass OF box and behavior 
was recorded for 10 minutes. After a 10 minute recorded session in the OF box, each 
mouse was returned to its original cage, and the OF box was cleaned thoroughly with 
ethanol before the next mouse was tested. 
NORT test: After the OF test, each mouse was given a 90 minute rest interval, and then 
each mouse was returned to the OF cage containing two identical, equally-spaced objects 
that met the criteria previously described (128). After a 5 minute learning interval, each 
mouse was returned to its original cage for 90 minutes. Next, each mouse was put back 
in the OF cage, this time containing one familiar object from the previous session, and a 
novel object. The mouse was recorded for 5 minutes, and behavior was analyzed using 
Noldus Ethovision XT 12 software.   
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1.9.7 Significance 
The research proposal described above was designed to comprehensively evaluate 
whether the patient-derived CSF-tropic strain of Bb, Bb297, could produce persistent 
infection in the CNS of LD-susceptible C3H/HeN mice. Our approach also provided 
information about neuroimmune changes that were associated with Bb infection. Finally, 
we assessed whether any behavioral deficits were associated with Bb infection, an 
approach that to date has not been used in the context of experimental LD. Collectively, 
this research helped to determine whether infection with Bb 297 in C3H/HeN mice could 
serve as a novel experimental mouse model for neuroborreliosis, and it elucidated some 
possible mechanisms that Bb or other pathogens could utilize to establish infection in the 
CNS. 
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2. GAMMA DELTA T CELLS AND DENDRITIC CELLS IN REFRACTORY 
LYME ARTHRITIS* 
 
2.1 Synopsis 
LD is a multisystem infection transmitted by tick vectors, and it is the fastest growing 
vector-borne disease in the United States. The primary treatments are oral or intravenous 
antibiotics. Despite treatment, some individuals do not recover and have prolonged 
symptoms affecting multiple organs, including the nervous system and connective 
tissues. Inflammatory arthritis is a common symptom associated with Lyme pathology.  
In the past decades, γδ T cells have emerged as candidates that contribute to the 
transition from innate to adaptive responses. These cells are also differentially regulated 
within the synovia of patients affected by RLA. Here we review and discuss potential 
cellular mechanisms involving γδ T cells and DCs, in RLA. Toll-like receptor signaling 
(TLR) and antigen processing and presentation, will be the key concepts we review in 
aid of understanding the impact of γδ T cells in RLA. 
 
2.2 Introduction 
LD is a multisystem tick-borne infection primarily affecting the joints, heart, and 
nervous system (40, 129). As we have described, compared to other vector-borne 
diseases, there is a relatively high incidence of LD in the United States (102). The 
                                                 
* Reprinted with permission from “γδ T cells and Dendritic Cells in Refractory Lyme Arthritis” by Ali 
Divan, Ralph C Budd, Richard P Tobin and M.Karen Newell-Rogers, 2015. J. Leuk Biol, 97, 653-63, 
Copyright [2015] by Federation of American Societies for Experimental Biology. 
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infection is caused by the Bb spirochete, which is transmitted through the salivary glands 
of a tick during a blood meal (130). The minimum time requirement for tick-to-skin 
attachment and Bb dissemination is 24-48 hours, although this can vary depending on 
whether the tick has had previous blood meals in the same day (131). At present, only 
two species of ticks are known to transmit LD, the Blacklegged tick Ixodes scapularis, 
and the Western Blacklegged tick Ixodes pacificus (102). If LD is detected within the 
first few weeks of infection, treatment with oral or intravenous antibiotics is generally 
effective. If treatment is delayed, systemic dissemination and continued symptoms can 
present challenges to therapy. In some individuals, antibiotic treatment does not provide 
relief of symptoms. Instead, these patients manifest chronic states of inflammatory 
disease. Evidence suggests that the pathology of these chronic diseases can be attributed 
to either autoreactive immune cells and/or persistent infection (132-135). These chronic 
diseases are called PTLDS when there is multisystem involvement, or RLA when the 
involvement is predominantly in the joints. Lyme advocacy groups, researchers, and 
clinicians disagree as to whether the symptoms of these lingering diseases are from 
chronic infection or immune dysfunction or both (40, 134, 136-140). Recent reports in 
the literature describe persistent levels of flagellin B DNA and Bb cell bodies in multiple 
tissues up to 12 months after antibiotic treatment. Bb bodies that exist within these 
tissues are uncultivable, but surprisingly xenodiagnosis with ticks reveals new 
spirochetal forms within tick tissues (135). This suggests that non-cultivable spirochetes 
may either be dormant, or are sufficiently immunogenic to cause prolonged pathology 
and symptoms. Other work shows persistent increases in Bb antigens, DNA, and RNA in 
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the tissues of RMs, despite receiving aggressive antibiotic treatment in the late 
disseminated period of infection (133). This further supports the hypothesis that an 
initial tick bite can result in persistent infection. These studies underscore the importance 
of early treatment, and they bring into question whether treatment success may depend 
on a balance between effective adaptive immune responses, and long-lasting innate 
responses.  Furthermore, the timing of clinical intervention, as it relates to host immunity 
and pathogen burden, may determine the outcome of LD on the basis of effective and 
regulated antigen processing and presentation. Thus, despite contention between 
paradigms of chronic infection versus immune dysfunction, a combination of Bb 
persistence and/or immune dysfunction could also result in a state of chronic disease. 
 
Both PTLDS and RLA have associations with TLR1 polymorphisms, and HLA-DR 
haplotypes (141, 142). Symptoms of PTLDS include mild to severe musculoskeletal 
pain, fatigue, as well as difficulties in concentration, loss of cognitive abilities, and loss 
of memory. RLA is marked by persistent polyarthritis of the joints, especially in at least 
one knee (134, 143, 144). Both syndromes are debilitating and can decrease the quality 
of life. 
 
An important T cell subset, the γδ T cell, has been at least partially characterized over 
the last two decades.  Several laboratories and investigators have focused on these cells 
in both infectious and autoimmune diseases. Of particular interest, is our work that has 
focused on elucidating the signaling pathways and the molecular mechanisms used by 
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(DCs) and γδ T cells in RLA (105, 141, 143-146). Our group’s work includes cloning γδ 
T cells from the synovial fluids of RLA patients, characterizing changes in Fas ligand 
(FasL) expression, and investigating caspase signaling events in response to FasL 
signaling (105, 145, 146). Here, we will focus on the immune responses in RLA, with 
specific focus on DCs and γδ T cells. Additionally, we will discuss an antagonist peptide 
that affects survival signals on polarized antigen presenting cells (APCs), and we will 
discuss its potential role in treating RLA. 
 
2.3 γδ T Cells in Inflammatory and Infectious Diseases 
γδ T cells were first observed in the peripheral blood of humans in the 1980’s (147). 
These cells are characterized by the expression of the T cell receptor gamma and delta 
chain genes located on chromosomes 7 and 14, which rearrange in a manner similar to 
V(D)J recombination in αβ T cells (148).  In contrast to αβ T cells, however, the γ and δ 
chains of the T cell receptors (TCRs) need not be disulfide linked. Whether disulfide 
linkage occurs depends on the expression of the constant regions Cγ1 vs Cγ2, both of 
which are contained within the TCR gamma locus (149, 150). Besides structural 
differences in their TCR, these cells are unique because they have the ability to respond 
to non-classical MHC antigens, such as CD1a-c (151, 152) or CD1d (153, 154). γδ T 
cells are also differentially regulated in a variety of infectious and inflammatory 
diseases. For example, in murine relapsing/remitting experimental autoimmune 
encephalitis (EAE), the γδ T cell subset expressing Vγ4 is elevated in the CNS both 
during disease onset and relapse, but not during remission. Interestingly, the γδ T cell 
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subset expressing the Vγ1 TCR is found at the highest frequency in the CNS during 
remission.  Consistent with the above functional associations, treatment with activating 
antibodies against Vγ1 is associated with decreased disease severity and decreased IL-17 
production. In contrast, during all phases of EAE, Vγ4 activating antibodies increase 
disease severity and IL-17 production (155). In rheumatoid arthritis (RA) Vγ9Vδ2 T 
cells are elevated in frequency in the synovial tissues of human patients, and in contrast 
to MS, this subset is the primary subset that produces IL-17 and IFN-γ (156-158). 
Importantly, γδ T cells can be regulated by different subsets of natural killer T cells 
(NKTs) (159).  In murine Coxsackievirus-induced endocarditis, there are increases in 
Vγ4 T cells, while invariant NKT cells (iNKT), and T regulatory cell (Treg) cells and 
their responses are decreased.  Protection against endocarditis is associated with 
increased iNKT activation, decreased activation of Vγ4 T cells, and increased Treg 
responses (159).  γδ T cells have also been implicated in granulomatous mycobacterial 
infections, such as leprosy and tuberculosis (160, 161), as well as parasitic infections 
mediated by multiple Plasmodium species (162, 163). Collectively, these studies 
demonstrate that γδ T cells are important in inflammatory and autoimmune diseases.  
Below we summarize what is known about γδ T cells in LD and RLA.   
 
2.4 Characterization of γδ T cells in Lyme Arthritis 
Interest in γδ T cells expanded significantly during the 1990s. A few groups focused on 
γδ T cells in RLA. In these studies, synovial tissues from RLA patients showed distinct 
increases in the Vδ1+ subsets of γδ T cells (164). Although many studies have 
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documented the presence of γδ T cells in the synovial fluid of RLA, it remains unclear 
which APCs are most important γδ T cell activation. Some suggest that B-cells are the 
primary APCs, while others show that DCs may be more important (165-167). 
Sometimes γδ T cells themselves can serve as APCs. We will focus on DCs, as the APCs 
of interest, because some evidence suggests DCs are the most important antigen 
processing and presenting cells in RLA (146). 
 
2.5 γδ T cells and the Dendritic Cell 
In LD, γδ T cells require both an APC, and activating cytokine(s) (146). Flow cytometric 
analyses of RLA-derived γδ T cells demonstrate that IL-2, DCs, and Bb antigens are 
necessary to cause FasL and CD25 expression on γδ T cells. In the absence of DCs, or 
Bb sonicate, no increases in FasL or CD25 are observed. Consistent with these findings, 
others report that γδ T cells and DCs both contribute to the immune response against 
infectious pathogens, including malaria, West Nile virus, and sepsis (168-171). In RLA, 
Fas:FasL interactions are the initiating events for reciprocal maturation/activation of 
DCs and γδ T cells (105). These events are also associated with increased IL-12 
production and increased cell surface expression of CD40 and CD86, well-described co-
stimulatory molecules, on DCs.  As a result of the increased co-stimulation, the DC 
serves to activate the γδ T cell as reflected by an increase in the activation marker CD25 
(Figure 2.1 A) (105). The increase in FasL may be surprising because FasL expression is 
often assumed to be exclusively associated with cell death pathways, although recent 
work has demonstrated that this is not necessarily the case (172-176). In fact, Fas:FasL 
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signaling can have a variety of different outcomes (172-174, 176). Below we discuss the 
Fas:FasL signaling mechanisms that may be important in RLA.     
 
2.6 Fas:FasL Signaling in Murine Lyme Polyarthritis Models 
To understand the role of FasL expression on γδ T cells in RLA, Shi et al addressed the 
question using C3Hgld mice, a mouse strain with a non-functional mutation that results 
in defective FasL expression (145). Using this mouse model, the investigators show that 
mice deficient in FasL sustain reduced cytokine responses to Bb, and have decreased 
incidence and severity of polyarthritis (145). Interestingly, there is no difference in the 
Bb burden or antibody titers to Bb between C3Hgld mice and controls, suggesting that 
the Fas:FasL receptor:ligand pathway does not directly impact the  number of 
spirochetes during the infection. Instead, Fas:FasL signaling between CD4 T cells, DCs, 
and γδ T cells has been proposed to be  part of the proinflammatory response during 
Lyme polyarthritis and RLA (145). In parallel, in human synovial fluids collected from 
RLA patients, FasL selectively induces apoptosis of Fashigh CD4 T cells, whereas 
approximately 90% of FasLow CD4 T cells remain viable (164). It has not yet been 
reported whether the FasLow CD4 T cells become activated and/or produce inflammatory 
cytokines in response to FasL on γδ T cells. However, if they produce inflammatory 
cytokines, this finding would be consistent with the results obtained using the C3Hgld 
mouse model.  
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The consequence of Fas engagement by FasL appears to be determined by the activation 
of downstream accessory proteins, including Fas Associated Death Domain (FADD)-
containing molecules, FADD-like IL-1β converting enzyme (FLICE), and/or cellular 
FLICE-inhibitory protein (c-FLIP). Cell death is associated with recruitment of FADD-
containing molecules, whereas c-FLIP serves as an inhibitor of Fas-dependent apoptosis 
(177-179).  DCs are known to produce high levels of c-FLIP, levels greater than those 
reported for other monocyte-derived cellular populations (180). Multiple studies in 
Lyme and non-Lyme models show that there is a direct correlation between c-FLIP 
expression and DC resistance to Fas:FasL mediated apoptosis (105, 180-182). In fact, 
downregulation of c-FLIP correlates with increased sensitivity to Fas:FasL-induced 
apoptosis, whereas overexpression of c-FLIP is associated with cell survival. 
Interestingly, c-FLIP expression in DCs increases in response to TLR4 activation with 
LPS (180). In addition, when T cells are activated via TCR/CD3 signaling, c-FLIP can 
serve to promote IL-2 production by the activated T cells through the ERK and NFκB 
pathways (182).  Furthermore, c-FLIP confers protection from apoptosis for the 
TCR/CD3 activated cells (182).
   
 
47 
 
 
Figure 2.1 Fas:FasL interactions. A, Death signaling pathway initiated by Fas:FasL 
binding in a DC. Fas Associated Death Domain (FADD) binds the cytoplasmic domain 
of Fas and recruits caspase-8 to activate RIP-1 and initiate apoptosis. B, Alternative 
Fas:FasL signaling pathways are controlled by cellular FLICE-inhibitory protein (c-
FLIP). c-FLIP inhibits signaling from the death-inducing FADD/caspase8 complex and 
diverts the signals toward the mitogen-activated protein kinase (MAPK) pathways 
(AKT, JNK, Wnt) NF-κB pathway, or ERK pathways resulting in survival, cytokine 
production, and/or proliferation. These pathways are not mutually exclusive 
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Based on these observations, Shi et al propose that c-FLIP is the Fas-associated element 
that is responsible for Fas-dependent proliferation, differentiation, and/or cytokine 
secretion in DCs. c-FLIP could act to prevent the activity of FADD in causing Fas-
mediated cell death by diverting the Fas:FasL death signal from the FADD/caspase-8 
death pathway, toward the MAPK/ERK pathway by way of the association of the 
serine/threonine kinase Raf1 with c-FLIP (183-186). Alternatively, TNF receptor 
associated factor 2 (TRAF-2) and receptor-interacting protein 1 kinase (RIP1) could bind 
c-FLIP and trigger the NF-κB pathway resulting in inflammation (187). In either case, 
both MAPK and NF-κB pathways regulate increases in TNF-α and the proinflammatory 
cytokine IL-12, as illustrated in Figure 2.1B (105, 188, 189). These mechanisms explain 
two possible ways in which Fas:FasL signaling between Bb-stimulated γδ T cells and 
DCs may promote production of TNF-α and IL-12, thereby contributing to RLA.  
 
The above possibilities are consistent with the observation that C3Hgld mice deficient in 
Fas:FasL interactions have reduced joint inflammation in response to Bb infection 
(145).In fact, when C3Hgld mice are infected with Bb, their CD4 T cells produce 
significantly less IFN-γ and IL-4 than their wild type counterparts (145), suggesting that 
Fas:FasL signaling affects CD4 T cells as well as other lymphocyte populations. 
Currently, little is known about the outcome of Bb infection in Fas-deficient lpr mice. 
Because lpr mice do not express the Fas receptor, they will serve as an important model 
system to better elucidate the contribution of Fas:FasL interactions in murine Lyme 
polyarthritis and human RLA. 
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2.7 γδ T Cell Activation Depends on TLR2 in Lyme Disease 
The lipidated outer surface proteins A and C (OspA, OspC), that are produced by Bb, 
have been demonstrated to cause inflammation via TLR2 signaling in monocytes and B 
cells (190). TLR2 signaling pathways are also important for γδ T cell activation (104). 
When DCs and γδ T cells are combined with IL-2 and either lipidated or non-lipidated 
OspA, the outcomes are quite different, respectively. In the case of lipidated OspA, γδ T 
cell proliferation and activation occurs with similar magnitude as exposure to whole Bb 
sonicates (104). In contrast, treatment with non-lipidated OspA results in no net 
proliferative effect. These contrasting outcomes reveal that the TLR2 signaling 
pathways, necessary for DC and γδ T cell signaling in response to Bb, depend heavily 
upon the lipid modifications of the TLR agonist. The contribution of TLR signaling in 
DCs and γδ T cells is further supported by studies using MyD88-/- mice. The 
downstream effects of TLR2 engagement require MyD88, a complex of signaling 
molecules that lead to cellular activation (191-193).  Loss of MyD88 in DCs prevents 
activation of γδ T cells, regardless of the lipidation state (lipidated versus non-lipidated) 
of OspA. Antibodies blocking TLR2 binding also prevent γδ T cell activation (104), 
further supporting the hypothesis that TLR2 may be an important mediator of γδ T cells 
in RLA.  
 
The requirements for physical contact between Bb-exposed γδ T cells and DCs has been 
investigated (104). In the absence of physical contact between γδ T cells and DCs, 
treatment with Bb sonicate failed to activate the γδ T cells, as measured by upregulation 
   
 
50 
 
of cell surface CD25. This suggests that contact between γδ T cells and DCs is necessary 
for γδ T cell activation. Furthermore, fixation of DCs prior to Bb antigen exposure 
prevents CD25 upregulation, underscoring the requirement for DC metabolic activity in 
γδ T cell activation (104). In contrast, γδ T cell activation is not affected by antibodies 
blocking MHCI or MHCII molecules, although blocking the γδ TCR does have an 
inhibitory effect (104). This indicates that signaling through the γδ TCR is necessary for 
cell activation in response to Bb sonicate, but that the γδ TCR is not necessarily 
restricted to classical MHC I or MHC II molecules.  Interestingly, blocking caspase 
activity with the pan-caspase inhibitor zVAD also prevents CD25 upregulation and 
inhibits downstream cytokine responses as evidenced by decreases in IL-1β, IL-12, and 
IL-6 (190). Collectively, these data suggest that TLR2 signaling, and physical contact 
between metabolically active DCs and γδ T cells are required for γδ T cell activation in 
response to Bb. Furthermore, these interactions are not necessarily MHC restricted to 
classical MHCI or MHCII molecules, although both the γδ TCR and caspase activity are 
necessary in DCs.   
 
Although some investigators have shown that γδ T cells from human blood can express 
TLR2 receptors, this does not appear to be the case in γδ T cells isolated from RLA 
synovial tissues (104). In fact, γδ T cells bearing Vδ2Vγ9 subsets of γδ T cells are the 
only known subsets that produce robust responses to TLR2 ligands without help from 
DCs (194, 195). The Vδ2Vγ9 subsets of γδ T cell subsets are the most common subset in 
human peripheral blood. However, this same subset represents a minority of the γδ T 
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cells in RLA synovia, where the most frequent subset expressed is Vδ1 (194, 195). 
Interestingly, both Vδ1 and Vδ2Vγ9 subsets can produce increased cytokine responses, 
including IFN-γ and IL-8, when their TCRs are stimulated with anti-γδ TCR antibody 
and TLR2 ligands (194, 195). This implies that TLR2 may costimulate γδ T cells, either 
directly or indirectly, resulting in cytokine production.  Thus, TLR2 may serve a 
costimulatory role for γδ T cells analogous to the proposed costimulatory role for TLR2 
in αβ T cell activation (196). Because of the abundance of Vδ1 subsets in RLA (164), 
and because these subsets are not directly activated in response to TLR2 stimulation, γδ 
T cells may depend on other cellular populations to become activated in RLA. Based on 
the evidence cited above, γδ T cells likely become indirectly activated by TLR2 agonists 
through physical cell:cell contact that triggers caspase activity in metabolically active 
DCs,  as illustrated in Figure 2.2. A similar interpretation has been reported for other 
non-RLA models of disease (197).  
 
2.8 Non-classical Antigen Presentation in Lyme Disease and RLA 
Unlike the αβ TCR that has been widely characterized as recognizing antigens only 
when presented by classical MHC class I or II molecules, the specificities of γδ TCRs 
remain controversial, as they are thought to bind a variety of cognate ligands. The MHC-
like non-classical molecules, the CD1 proteins, have become the focus of many studies 
involving γδ T cells, iNKTs, and NKT cells (154, 198, 199). CD1 molecules can present 
amphipathic moieties, including lipids, lipopeptides, and glycolipids, that appear to help 
γδ T cells differentiate self from non-self (200). The group two CD1 protein, CD1d, is  
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expressed constitutively on DCs (201).  Evidence shows that Bb peptides can be 
presented via CD1d, and can activate NKT cells to respond to Bb infection (201-
203).Unlike CD1d molecules, the group one CD1 proteins, CD1a/b/c, are not 
constitutively expressed in DCs (204), but instead upon TLR activation that results in 
IL-β secretion, CD1 group one molecules are synthesized de novo (109, 205, 206). The 
peak expression of CD1 group 1 proteins occurs approximately 72 hours after 
stimulation with microbial products, likely due to the time required for transcription, 
translation, and proper folding (205, 206). 
 
In Bb infection TLR2 signaling contributes to the activation of DCs (109). The activated 
DCs produce IL-1β, that in turn, activates neighboring DCs to begin the de novo 
synthesis of CD1 group 1 proteins. In the absence of TLR2 activation, IL-1β is sufficient 
to induce CD1 group 1 surface expression, suggesting that other IL-1β inducing 
pathways could also produce similar results (109). In contrast, blockade of IL-1β 
completely prevents CD1 group one expression, highlighting the importance of IL-1β in 
CD1 group 1 expression. Interestingly, IL-1β has no apparent effect on CD1d, implying 
that the CD1 group one and group two proteins may be differentially regulated, and 
serve different functions (109). CD1a/b/c are especially relevant in LD (109). In humans, 
all three of these isoforms are inducible in dermal DCs exposed to Bb antigens (109). Of 
the three isoforms, CD1c levels are the most responsive and exhibit the highest levels of 
expression, upon encounter with Bb lipopeptides (109). Though it has yet to be studied 
in RLA, multiple investigators show that Vδ1 T cells can respond to lipopeptides 
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presented via CD1c on DCs (152, 207, 208).  Because the Vδ1 subset is prevalent in the 
synovial tissues of RLA patients, it is possible that the Vδ1 subset of T cells can also 
respond to CD1c presenting Bb lipopeptides. In summary, Vδ1 γδ T cells are prevalent 
in RLA inflammatory sites, Bb antigens induce upregulation of CD1a/b/c on DCs, and 
Vδ1 γδ T cells respond to lipopeptides presented by CD1a/b/c on DCs. These 
observations provide evidence that CD1 group one proteins may be relevant in RLA. 
 
One possibility is that CD1 group one proteins present self-lipopeptides, priming 
autoreactive γδ T cells that contribute to the pathology of RLA. Alternatively, CD1 
group one proteins may be presenting Bb antigens that have been trapped in collagen, 
thereby causing γδ T cells to produce chronic inflammatory responses.  Consistent with 
the latter scenario, Lyme antigens can persist from months to years in the joints and 
synovial fluids of Bb infected mice (103). Taken together, the data are consistent with 
the idea that non-classical antigen presentation may be relevant in the pathology of LD 
and RLA. 
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Figure 2. 2 OspA activates dendritic cells via TLR engagement. TLR signaling 
initiates a caspase dependent upregulation of surface proteins that are essential for 
binding and activating the γδ T cell. These signals may include Fas, Cd1, γδ TCR 
ligands, or a variety of co-stimulatory receptors that bind the TCR. In addition, IL-6 and 
TNF-α are secreted, while IL-2 is produced either by Th1 polarized CD4 T cells or DCs. 
Both γδ TCR and Fas:FasL binding are essential for CD25 upregulation and γδ T cell 
proliferation. Co-stimulatory ligands shown on γδ T cell are likely to play a role in the 
activation signal. These can include CD2, Inducible T cell costimulator (ICOS), CD28, 
CD27, CD30, and natural killer group 2, member D (NKG2D).  
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2.9 The Reciprocal Roles of Caspases  
Caspases are cysteine-dependent proteases that cleave proteins at aspartic acid residues 
(209).  The caspase family of proteins are involved in cell signaling pathways related to 
apoptosis, cell survival, and differentiation (210). Fas and FasL can have multiple, and 
sometimes opposing, roles in the Fas:FasL signaling process. For example, inhibition of 
caspase-8 by c-FLIP promotes DC survival and induces the proinflammatory cytokines 
IL-12 and TNF-α (105, 182). In contrast, caspase-8 activity is upregulated in Bb 
activated DCs, and it remains elevated above resting monocytes, suggesting that it is 
necessary for their activation. Furthermore, monocytes require some caspase-8 activity 
to differentiate into immature myeloid DCs (104). Thus, the regulation of caspase-8 
appears to be a key determinant in cell fate decisions. Downstream accessory proteins 
that associate with caspase-8 can also determine cell behavior in monocytes and DCs. 
For instance, recent work shows c-FLIP can have at least two different ways of 
interacting with caspase-8 in DCs. Cleaved c-FLIP can compete with caspase-8 for the 
FADD death effector domain, which diverts the signal away from apoptosis. 
Interestingly, full length c-FLIP ligand (c-FLIPL) can heterodimerize with caspase-8 and 
produce a cleavage product called p43FLIP (211). In turn, p43FLIP induces proliferation 
and differentiation through the ERK and NF-κB pathways (211). Thus, levels of 
caspase-8, and changes in its associated downstream proteins can produce a variety of 
effects in DCs and monocytes (211).   
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Caspase-1 cleaves pro-IL-1β into IL-1β (212) and, as discussed, IL-1β is essential for 
non-classical antigen presentation. The inflammasome components that assemble 
caspase-1 have also been implicated in the pathology of RLA (213, 214). Although some 
investigators showed that the inflammasome component nod-like receptor family, pyrin 
domain containing 3 gene (NLRP3) is necessary for caspase-1 assembly (215), it does 
not appear to be relevant in Lyme arthritis (214). In Bb infected NLRP3 KO mice no 
differences were observed in either the quantity of caspase-1 production or joint 
inflammation when compared to infected WT controls. In contrast, the inflammasome 
component apoptosis-associated spec-like protein containing a carboxy-terminal CARD 
(ASC) contributes to RLA, as loss of this component significantly decreases the levels of 
caspase-1 and the magnitude of arthritis severity (214). Thus, caspase-1 is important in 
RLA, with significant contribution from ASC independent of NLRP3. Thus, both 
caspase-8 and caspase-1, and their respective neighboring proteins, are involved in 
pathologies associated with Bb infection.  The effects of caspase-8 depend upon the 
accessory proteins, cFLIP and cFLIPL and the associated cleavage product, p43cFLIP, 
whereas the effects of caspase-1 and its contribution depend on the inflammasome 
component ASC that contributes to IL-1β production as an important step in non-
classical antigen presentation. Interestingly, IL-1β can also potentiate Th17 type 
responses. 
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2.10 IL-17 in RLA 
IL-17 is another important cytokine in inflammatory responses during infection (216-
221). IL-17 has been implicated in multiple human diseases, including psoriasis, RA, 
multiple sclerosis, ankylosing spondylitis, inflammatory bowel disease, asthma, and LD 
(216-221). There are many cell types that can produce IL-17, the most well-known of 
which is a subset of retinoic acid receptor-related orphan receptor gamma/alpha 
(RORγ+/RORα+) T cells, called Th17 T cells (222, 223).  Th17 cells are thought to 
develop and progress through three stages, including differentiation, amplification, and 
stabilization-all of which are dependent on continued signal transducer and activator of 
transcript 3 (STAT3) activation, through a variety of cytokine combinations, the most 
important of which are thought to be IL-6, TGFβ, IL-21 and IL-23 (223). For example, 
Th17 cells can differentiate from naïve CD4 T cells after exposure to IL-6 and TGFβ, 
resulting in the production of inflammatory cytokines, including IFN-γ, TNF-α, IL-17A 
and IL-17F , as a part of the key mechanism(s) in fighting infection (223). In the absence 
of IL-6, TGFβ can upregulate forkhead box P3 (FoxP3), that antagonizes RORγ, and 
RORα, thus inhibiting the Th17 program and causing differentiation of naïve CD4 T 
cells into inducible T regulatory cells (iTregs), that can function to suppress 
conventional antigen-specific T cell responses (223). Importantly, IL-21 can substitute 
for IL-6 in promoting Th17 cell differentiation, supporting the observation that multiple 
cytokine combinations can lead to Th17 differentiation (222, 223). Furthermore, IL-1β 
and TNFα prevent the Th1 and Th2 promoting cytokines, IFN-γ and IL-4, and in doing 
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so, IL-1β and TNFα provide an environment in which Th17 differentiation can occur 
(222). 
 
Importantly, IL-17 can recruit and stimulate fibroblasts, endothelial cells, and epithelial 
cells to produce IL-6, TNFα, IL-1β, granulocyte macrophage colony stimulating factor 
(GMCSF), nitric oxide, and a number of matrix metalloproteases (MMP), all of which 
can contribute to IL-17 feedback loop amplification, germinal center formation and 
antibody production (222, 224). As an example of an inflammatory disease, IL-17 is 
relevant to the pathology of RA. In fact, clinical trials show that antibody-mediated 
blocking of the IL-17 receptor, or neutralizing antibodies to IL-17, delay RA progression 
and joint damage (225, 226). IL-17 is especially important in RLA. A study shows that 
48% (13/27) of CDC confirmed Lyme+ RLA patients produce serum antibodies against 
the Bb virulence factor, neutrophil activating protein (NapA) (227). Importantly, the 
production of anti-NapA antibodies is unique to RLA, as patient control groups with RA, 
sepsis, or pneumonia do not produce any circulating NapA antibodies. Likewise, patients 
with acute diagnoses of Lyme do not produce antibodies to NapA, suggesting that this 
antibody is specific for RLA.  Consistent with the interpretation that NapA is specific to 
RLA, in synovial T cells isolated from RLA patients that produce serum NapA 
antibodies, IL-17 production is abundant in response to NapA antigen challenge (227). 
Also, in accordance with other RLA models, synovial T cells can only produce IL-17 in 
response to NapA in the presence of DCs (227). Furthermore, NapA can induce DCs to 
produce Th17 promoting cytokines, which in turn prime the Th17 responses that 
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contribute to damaging inflammation and arthritis (227). These investigations 
demonstrate that IL-17 is a relevant pathological factor in RLA.  
 
Multiple γδ T cell subsets can produce IL-17 in response to bacterial infections by 
L.moncytogenes, E.coli, S.aureus, and M.tuberculosis (MT) (228-231). In the case of 
MT, infected DCs also produce significantly increased levels of IL-23 that in turn, drive 
production of IL-17 by γδ T cells, but not CD4 T cells (232). These observations suggest 
that IL-17 is an important cytokine in recovery from infection, but other data suggest a 
pathological role for IL-17 in conditions of chronic inflammation, including arthritic 
autoimmune conditions, such as RA and RLA, as discussed above (225-227). While 
there is a clear association between elevated IL-17 production and RLA, it is not known 
whether the source of IL-17 is γδ T cells. If the immune responses in RLA are similar to 
those of MT infection, then DCs and γδ T cells could provide novel drug targets to treat 
RLA.    
 
2.11 γδ T Cells in the Transition Between Innate and Adaptive, Specific Immunity 
During infections with organisms such as Listeria, Leishmania, various mycobacterial, 
plasmodial, and Salmonella infections, γδ T cells are among the “first responders” as a 
part of the early response to an acute infection (233-237).  However, an increased 
frequency of γδ T cells is also observed in the inflamed tissues in various inflammatory 
diseases, including celiac disease, RA, RLA, and sarcoidosis, suggesting that γδ T cells 
may be contributing to the pathology of these and other diseases, and implicating γδ T 
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cells in both recovery from infection as well as in chronic inflammatory syndromes (164, 
175, 238, 239).Consistent with their roles in acute responses to infection and their roles 
in inflammatory diseases, some have proposed that γδ T cells may bridge the transition 
between innate and adaptive immune responses, as has been suggested in MT infection 
(240-242). Thus, although γδ T cells may be helpful in fighting an initial infection, they 
may also contribute to a variety of potentially post-infectious syndromes and 
inflammatory diseases in which some individuals develop chronic inflammation.  
 
As an example of the dual contributions of γδ T cells, γδ T cells of the Vγ9Vδ2 subset 
produce cytokines in response to soluble MT antigens and lipopeptides during an acute 
MT infection. Consistent with their contribution to innate immunity during the infection, 
the Vγ9Vδ2 subset of γδ T cells can initially respond to MT infection in the absence of 
other APCs (243). However, the presence of professional APCs accelerates the 
production of pro-inflammatory cytokines by Vγ9Vδ2 T cells and suggests that γδ T 
cells can contribute to an immune response through mechanisms involving APCs (243, 
244). Additionally, γδ T cells can exhibit memory phenotypes subsequent to their initial 
activation and expansion, and because memory is a key feature of adaptive immunity, 
the presence of memory phenotypes further supports the role of γδ T cells in adaptive, 
specific immunity (245). In support of this correlation, it has been reported that up to 
90% of circulating Vγ9Vδ2 T cells exhibit memory phenotypes (246).  
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Shi et al, investigated γδ T cells in LD and RLA (108). They demonstrated that WT mice 
infected with Bb for 4 weeks show significant increases in the number of activated 
CD44+ γδ T cells within their lymph nodes. In contrast, Bb infection of either TLR2-/- or 
γδ TCR-/- mice resulted in no net expansion of γδ T cells (108). Importantly, the γδ T 
cell deficient animals had significantly lower numbers of CD4 T cells, CD8 T cells, and 
B cells in the lymph nodes subsequent to Bb infection, supporting the notion that γδ T 
cells are required for an effective transition from an innate to an adaptive immune 
response during Bb infection. Both mutant strains of animals produce much lower levels 
of IL-6, IL-12, IFN-γ, TNF-α and IL-1β in response to Bb infection. Moreover, the DCs 
from TLR2-/- animals do not release IL-17 in response to Bb (108). These studies show 
that both TLR2 receptors on DCs and the γδ TCR on γδ T cells are necessary for pro-
inflammatory cytokine responses, and expansion of B and T cells within the lymph 
nodes, during Bb infection. TLR2, and γδ T cells, may therefore be important 
contributors to the effective transition between innate and adaptive immunity to Bb, 
suggesting that γδ T cells may be important in the pathology of RLA. 
 
2.12 Concluding Remarks on RLA 
The discussion above provides an overview of γδ T cells and DCs in RLA. The TLR2 
ligands (OspA, OspC, NapA) from Bb bind TLR2 receptors on DCs, which in the 
presence of IL-2 initiates caspase-8 dependent production of IL-1β (104). The sources of 
IL-2 are usually existing Th1 CD4 cells, though some have shown IL-2 can be produced 
by DCs as well (247-249). IL-2 binds its cognate receptor on γδ T cells and promotes 
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proliferation and activation, which increases surface CD25, and FasL (146). Meanwhile 
IL-1β binds neighboring DCs to initiate de novo production of non-classical antigen 
presenting proteins within the CD1 group one family (Figure 2.3 A). Within 72 hours, 
CD1a/b/c peak on DCs and they present amphipathic Bb lipids, lipopeptides and 
glycolipids to γδ T cells (109). Fas:FasL binding between DCs and γδ T cells induces γδ 
T cells to produce IFN-γ and IL-17 (108). At the same time γδ TCRs bind CD1 ligands 
presented by DCs, which in turn potentiates production of IL-6, IL-12, IFN-γ, and TNF-
α (108) as illustrated in Figure 2.3 B. Together, the DC and γδ T signal back and forth to 
produce a cytokine environment intended to clear infection. If the cytokine environment 
is out of balance, or lasts too long, it may become pathological. Based on the evidence 
we have presented, we propose that RLA is due to chronically activated synovial γδ T 
cells exposed to either live Bb or trapped Bb antigens. Thus, strategies for eliminating 
chronically activated γδ T cells could provide novel therapeutic approaches for treating 
RLA. 
 
2.13 Understudied Complications of LD 
As we have described, RLA is a relatively well-studied disease that is characterized by 
inflammation of the joints, centered around interactions between DCs and γδ T cells. It is 
important to note, that although there is no single treatment for RLA, clinical 
interventions that include treatment with disease-modifying anti-rheumatic drugs, or 
surgical intervention by synovectomies, are usually effective in remediating RLA 
symptoms (250).  Unlike RLA, PTLDS affects multiple organ systems, is not easily 
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diagnosed, and is relatively understudied. Furthermore, there are no therapies that have 
FDA approval for the treatment of PTLDS, and currently a general consensus of 
strategies for the treatment of PTLDS does not exist among clinicians. The paucity of 
research on PTLDS can be attributed in part to the lack of a suitable animal model for 
studying the disease. Moreover, the RM is the only animal that is routinely used to 
model neuroborreliosis, a condition that is thought to precede PTLDS (29). As we have 
described, use of the RM is a relatively inefficient and uneconomical approach. The lack 
of a mouse model that faithfully replicates neuroborreliosis underscores a major gap in 
our knowledge of LD and its associated complications, such as PTLDS.  In the 
manuscript that follows, we will describe our approach and the results of our 
experiments that were focused on addressing this major gap in knowledge. 
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Figure 2.3 Cell signaling between γδ T cells and DCs during Bb infection. A, Activated TLR2 initiates 
caspase-dependent production of IL-1β, IL-6, and TNF-α. IL-1β acts in an autocrine and paracrine manner 
to initiate de novo synthesis of Cd1 group 1 proteins.  Other cell surface proteins may become upregulated 
including Fas, γδ TCR ligands, and co-stimulatory molecules. B, Surface factors on DC and γδ T cells 
facilitate cognate interactions that initiate cytokine cascades involved in the transition to an adaptive 
immune response. Fas:FasL interactions lead to increased expression of CD25, production of IFN- γ, and 
of IL-17 by γδ T cells. Unknown γδ TCR ligands or CD1 group 1 proteins present antigen to the γδ TCR 
and induce the DC to secrete IL-6, IL-12, TNF-α, and other chemokines necessary for an effective 
transition to adaptive immunity. 
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3. EVIDENCE FOR LONG-TERM PERSISTENCE OF BORRELIA 
BURGDORFERI IN THE MENINGES 
 
3.1 Synopsis 
LD is a tick-borne infection caused by Bb, that has a global impact and a relatively high 
incidence in the United States (39). If not diagnosed and treated promptly, LD can result 
in musculoskeletal, neurological, and cardiac symptoms resulting in disability and 
sometimes death (40, 251). Some individuals that receive delayed antibiotic treatment 
experience persistent LD symptoms, a syndrome called PTLDS (29, 40). The etiology of 
PTLDS is unknown, however, persistent bacterial infection or neurologic auto-immune 
disease, or both, may underlie PTLDS (29, 252, 253). Few studies have focused on the 
effects of Bb on the CNS, and Bb has never been detected in the brain after experimental 
intradermal infection.  We hypothesized that intradermal infection with a CSF-tropic 
train of Bb that was derived from the CSF of a patient, would result in dissemination of 
Bb into the CNS. Here we show that infection with Bb 297 results in bacterial 
persistence in the dura, in immunological changes in the brain, and in behavioral 
deficits. We found that intradermal infection by Bb 297 resulted in the presence of CD4 
T cells and the B2 subset of B cells (B2 B cells) in the brain as early as 5 dpi, and CD4 T 
cells remained persistently elevated as long as 45 dpi. Remarkably, Bb spirochetes were 
detected in, and could be cultured from, the dura and the brain at 5 and up to 45 dpi. We 
observed significant behavioral deficits temporally associated with infection, including 
reduced pain threshold in the periphery, and impaired motor function.  Overall, our data 
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provide insight into the neuropathophysiology of LD, and suggest that neuroimmune 
responses that occur early in the course of Bb infection are not sufficient to clear 
infection, or to resolve behavioral changes that are associated with Bb infection. 
Moreover, our findings reveal that the dura is a viable niche environment for long-term 
bacterial infection.  
 
3.2 Introduction 
As we described in Chapter 1, the central hypothesis of this dissertation project was that 
Bb would establish persistent infection in the meninges of the brain, and that Bb 
infection would be associated with neuroimmunological changes and behavioral deficits. 
As part of testing this overall hypothesis, we established three aims. Our first aim was to 
determine if intradermal infection with Bb 297 would result in infection of the CNS, 
namely the brain or the dura, with the working hypothesis that both the brain and dura 
would become infected as early as 45 dpi. We formulated this hypothesis based on the 
fact that Bb 297 has a particular tropism for the CSF (111), and because it is known that 
the dura expresses proteins that Bb has high affinity for, such as collagen and decorin 
(114-117). We demonstrate below, that Bb did establish infection in the dura and the 
brain as early as 5 dpi, and that the infection persisted as late as 45 dpi. Our second aim 
was to determine whether there were any immunophenotypic changes in B or T cells in 
the dura or the brain, in response to intradermal Bb infection. We hypothesized that we 
would observe measurable changes in B and T cells, in both the dura and the brain. Our 
rationale for making this prediction was based on published findings in the literature that 
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Bb can induce B and T cell mediated pathologies in the periphery, and that 
neuroborreliosis has a tendency to elicit cytokine responses in the brain (23, 26, 31). We 
observed that multiple B and T cell subsets were detectable in the brain and dura of 
sham treated and Bb infected mice, and of particular note, B2 and CD4 T cells 
frequencies and numbers increased in the brain in response to Bb infection. Our third 
and final aim was to determine if long-term infection by Bb would result in behavioral 
changes. Based on the prediction that mice would manifest behavioral changes that 
paralleled the signs and symptoms of infection in humans, we hypothesized that mice 
would also exhibit behavioral changes that corresponded to deficits in pain sensitivity, 
mobility, and neurocognition (29, 123). Our data demonstrate that Bb infection results in 
behavioral deficits pertaining to pain sensitivity and mobility, however, changes in 
neurocognition, specifically visual memory, were not evident. Overall, our research 
resulted in the production a novel mouse model of neuroborreliosis that may be useful 
for understanding the pathophysiology of neurological LD.  
 
3.3 Methods 
Animals. Male C3H/HeN mice were purchased from Charles River Laboratories and 
were housed in temperature and humidity controlled rooms, housed in 12h/12h 
light/dark cycles. All procedures were in compliance with and approved by the 
Institutional Animal Care and Use Committee (IACUC) at Texas A&M University 
Health Science Center and Baylor Scott & White Health. All animals were 7-8 weeks 
old at the time of initial needle inoculation.  
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Bb culture and infection. Low passage Bb strain 297 was purchased from the American 
Type Culture Collection (ATCC), and was cultured in BSK-II medium at 37°C, 5% 
CO2, until it reached an approximate concentration of 2x107/mL. Bb spirochetes were 
quantified by dark field microscopy using a Petroff-Hausser chamber. Aliquots of Bb 
culture were diluted in BSK-II medium to achieve a concentration of 1x107/mL, and 
100uL of inoculum containing 1x106 Bb was administered intradermally in the dorsal 
thoracic midline. Sham animals were needle inoculated intradermally with 100uL of 
BSK-II medium. Bb passages were recorded, and all Bb used for infection had passage 
number less than 6. 
 
Tissue harvest and tissue culture. Prior to euthanasia, all mice were anesthetized by 
isoflurane, and each mouse was perfused transcardially with 60mL Ca++/Mg++ free, 
phenol red free, HBSS (Gibco #14185-052) over the course of approximately 5 minutes. 
Brain and DCLN were dissected, and dura was isolated from the skullcap as described 
(101). Tissues were aseptically transferred to 10mL of BSK-II medium and cultured in 
an incubator at 37C, 5% CO2 for 12 days. Samples were checked daily for Bb growth, 
and on day 12 of culture Bb concentration was quantified by darkfield microscopy. 
Acridine orange was added at a 1:1 ratio to the Bb culture, and samples were viewed by 
epifluorescence using a FITC filter set.  
 
Dextran Assay. Mice were anesthetized with isoflurane and injected via the retro-orbital 
sinus with 100uL of 2.5mg/mL 10KD FITC-dextran. After 3 minutes of circulation time, 
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20uL of blood was collected by facial vein puncture, and plasma was collected by 
centrifugation. 2uL aliquots of plasma samples were placed in 300uL formamide. After 
blood collection, mice were transcardially perfused with PBS, as described in “tissue 
harvest and tissue culture”. Mice were craniotomized, brains removed, weighed, and 
homogenized in 300uL formamide with a probe sonicator. All samples in formamide 
were incubated on a heating block at 55°C for 24 hours, followed by centrifugation at 
14,000rpm for 20 minutes. Supernatant from brain homogenates was drawn by Pasteur 
pipette, and transferred to 50uL formamide, and centrifuged again. 50uL aliquots of final 
supernatant from brain homogenates, and 50uL aliquots of plasma samples in formamide 
were sampled in triplicate to detect fluorescent emission by plate reader, using 
wavelengths 420ex/520em. Concentrations of dextran were determined by linear 
regression using a standard curve. 
 
Immunostaining. Skull caps and brains were removed and both were post-fixed in 2% 
paraformaldehyde for 24h at 4C.  Dura samples were permeablized in 0.1% Triton X-
100, and serum blocked in 2.5% goat serum/PBS containing 1:100 dilution of Fc block 
(BD 553142). Each dura was incubated in 1:200 rabbit anti mouse LYVE-1 IgG , and 
1:200 rat anti mouse CD31 IgG unconjugated polyclonal antibodies in 2.5% goat 
serum/PBS at 4C overnight. Dura samples were stained with fluorochrome-conjugated 
secondary antibodies at dilutions of 1:200 of Alexa 546 goat anti rabbit IgG (Invitrogen 
A11071), and of 1:200 Alexa 633 goat anti rat IgG (Invitrogen A21094) for 1 hour at 
room temperature. Afterwards, dura samples were incubated with 1:50 biotinylated 
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rabbit anti Bb polyclonal IgG (Invitrogen PA1-73007) at 4C overnight. Next, dura 
samples were stained with secondary antibody 1:200 Alexa 488 streptavidin (Invitrogen 
S11223) for 1 hour at room temperature. All dura samples were washed 3x for 5 minutes 
at room temperature between each step, and after the final staining step.  Brain samples 
were dehydrated in 30% sucrose overnight, followed by freezing in optimum cooling 
temperature (OCT) medium at -80°C. Each brain sample was cut into 50um sections 
using a cryostat, and every 3rd section was collected for immunofluorescent staining. 
Each brain sample was stained for 24 hours at room temperature in staining solution 
containing 0.1% Triton X-100, 2.5% goat serum, and 1:200 dilution of Alexa 555 Goat 
anti-mouse IgG. Each brain sample was washed 3x for 5 minutes at room temperature 
before mounting. All tissue samples were wet-mounted onto a positively charged glass 
slide and cover-slipped in Fluoromount-G with DAPI mounting medium (eBioscience 
0100-20). Tissues were imaged on Olympus IX-71 and Leica DMIRE 2 confocal 
microscopes and images were analyzed using FIJI-Image J software.   
 
Leukocyte isolation and flow cytometry. Dura were isolated as described, and leukocytes 
were freed from tissue by incubation for 30 minutes in 1mg/mL collagenase in HBSS 
supplemented with 5mM CaCl2. Next, using a 10mL syringe plunger, dura and brain 
samples were pushed through 100um strainers. Myelin was separated from the brain 
leukocyte suspensions using a 37% Percoll gradient as described (254). All cells were 
counted using a hemocytometer. Cells were stained on ice for 20 minutes with 
appropriate dilutions of Aqua viability dye, 1:100 (Invitrogen L34966); PE-conjugated 
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anti CD45, 1:100 (eBioscience 12-0451-83); APC-Cy7 conjugated anti-CD19 1:400 (BD 
557655); APC conjugated anti-CD5 1:100 (Biolegend 100625); FITC conjugated anti-
CD1d 1:100 (Biolegend 123508); PacBlue conjugated anti-IgD 1:100 (Biolegend 
405712); PacBlue conjugated anti-CD3 1:100 (Biolegend 100214); FITC conjugated 
anti-CD4 1:100 (BD 553651);  or APC conjugated anti-CD8 1:100 (Biolegend 100712), 
as described in table 3.5. Samples were washed in 3% newborn calf serum (NBCS), and 
analyzed using a BD FACS CANTO II flow cytometer. Antibody compensations were 
performed using BD CompBeads (BD 552845), Aqua compensation was performed 
using ArC Amine Reactive Compensation Bead Kit (Life Technologies A10346) and all 
gating was done based on fluorescence minus one (FMO) controls (not shown). Flow 
cytometric data was analyzed using FlowJo software.  
 
Von Frey pain test.  The Von Frey pain test was performed on an elevated surface with 
small holes in the base. Each mouse was allowed to habituate to the environment for 3 
minutes. The tip of the Von Frey filament was applied to the plantar surface of each hind 
paw. If a withdrawal response did not occur, the next largest filament was used. If a 
withdrawal response was elicited, the next lowest filament was used until no withdrawal 
response occurred. The filaments were then increased in size again until a withdrawal 
response occurred. This method was repeated until a single filament elicited 4 
consecutive withdrawal responses, indicating the end of one trial. Two trials were 
conducted on each hind-paw of each mouse per treatment group.  
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OF test. Each mouse was placed in a 31 cm x 32 cm plexiglass OF box and behavior was 
recorded for 10 minutes. This test also constituted the habituation phase for the NORT 
tests that followed. After a 10 minute recorded session in the OF box, each mouse was 
returned to its original cage, and the OF box was cleaned thoroughly with ethanol before 
the next mouse was tested. Behavior was analyzed using Noldus Ethovision XT 12 
software, and the following variables were analyzed: total distance moved, velocity, 
movement (averaging interval 15 samples, start velocity 2cm/s, stop velocity 0.5cm/s), 
time spent on floor, time spent on wall, time spent in each quadrant of floor, meandering, 
mobility state (Immobile threshold  5%, mobile threshold between 5% and 25%, highly 
mobile threshold ≥25%), and zone alteration between floor quadrants.   
 
NORT Test. After the OF test, each mouse was given a 90-minute rest interval, and then 
each mouse was returned to the OF cage containing two identical, equally spaced objects 
that met the criteria described (128). After a 5-minute learning interval, each mouse was 
returned to its original cage for 90 minutes. Next, each mouse was put back in the OF 
cage, this time containing one familiar object from the previous session, and a novel 
object. The mouse was recorded for 5 minutes, and behavior was analyzed using Noldus 
Ethovision XT 12 software. The following variables were analyzed: visits to novel 
object zone (nose point within 4cm of novel object), visits to familiar object zone (nose 
point within 4cm of familiar object), nose touching familiar object, nose touching novel 
object, nose point distance from each object, novel object exploration (nose point facing 
novel object while within 4cm of novel object), familiar object exploration (nose point 
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facing familiar object while within 4cm of familiar object). Testing schematic is 
illustrated in Figure 3.10.  
 
Statistical analysis. All data were analyzed and graphed using GraphPad Prism 7.0 
software. For tests involving multiple comparisons, two-way ANOVA was used with 
Holmes-Sidak correction for multiple comparisons, alpha = 0.05. For tests that did not 
involve multiple comparisons, unpaired t-test was used, alpha = 0.05. Power analysis 
was completed using GPower3 software and the following parameters: a priori analysis, 
difference between two independent means, Beta = 0.20, alpha = 0.05, and an effect size 
of 2.2 (based on preliminary data). Outliers were excluded by outlier test, alpha = 0.05. 
Animal randomization was not used in our approach, and investigators were not blinded 
to treatment groups. 
 
Data availability. Publicly available databases were not used to generate any of the data 
presented in this manuscript. 
   
 
74 
 
3.4 Results 
3.4.1 Dura Supports Bb Growth During Late-stage Infection 
Two species of ticks, Ixodes scapularis and Ixodes pacificus, are the accepted natural 
vectors for the transmission of Bb, the causative agent of LD (102). We aimed to 
establish a mouse model of neurological LD, by using an infection route that was 
relevant to the natural vector. Accordingly, we utilized needle inoculation via the 
intradermal route to inject ~1x106 Bb spirochetes belonging to the strain Bb 297, into the 
dorsal thoracic midline of LD susceptible C3H/HeN mice (88).  Because Bb 297 is a 
strain that was originally isolated from the CSF of a LD patient in the United States 
(111), we expected that it could have a tropism for the CNS. Mice were evaluated for 
LD infection during the early stage of the disease (255), 5 dpi, or during late-stage 
disease, 45 dpi, when neurological involvement may be expected (20). After performing 
transcardial perfusions, the brain, dura, and DCLNs of each mouse were removed, and 
each tissue was placed in BSK-II medium and cultured for 12 days. We assessed the 
tissues daily by dark field microscopy and we observed spirochete growth in all tissue 
types at 5 dpi, 45 dpi, and as early as 4 days after culture (Table 3.1-3.4). Aliquots of the 
culture were stained with acridine orange, and fluorescent spirochetes were visualized in 
all three tissues (Figure 3.1a, Table 3.1-3.4). Paraformaldehyde-fixed culture samples 
also demonstrated fluorescence when treated with Bb-specific antibody, providing 
confirmation that the observed spirochetes were Bb (Figure 3.2a-b).  
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To determine whether Bb persistence in the brain was specific to Bb strain 297, we used 
a green fluorescent protein (GFP) expressing variant of another common Bb strain, 
known as B31. Although we did not attempt to culture the brains of mice that were 
infected with B31, immunofluorescent staining with fluorochrome conjugated anti-GFP 
antibody did not reveal any spirochetes in any sections of the brain after 45 days of 
infection (data not shown). To rule out the possibility that GFP expression was 
preventing B31 from entering the brain, we infected mice for 45 days with wild-type 
B31, and using fluorochrome-conjugated anti-Bb polyclonal antibody, we did not detect 
any B31 in the brain (data not shown). Thus, it seems that CNS tropism may be a unique 
characteristic of Bb 297.  
 
A possible mechanism that could explain the presence of viable Bb in the brain is that 
Bb infection may compromise the integrity of the BBB, resulting in diffusion of Bb from 
the blood into the parenchyma or perivascular spaces of blood vessels in the brain. To 
test this possibility, we infected mice with Bb, and at the earliest time point that Bb was  
cultured from the brain (5dpi), we injected a 10 kilodalton fluorochrome-conjugated 
dextran (FITC-dextran) into the peripheral blood. We quantified the tracer signal 
spectrophotometrically, and we determined that the tracer signal was detectable in the 
plasma and brain homogenates of naïve mice (Figure 3.3a-b). No significant differences 
were apparent between sham and 5 dpi Bb-infected mice (Figure 3.3c). Our results 
suggest that the persistence of Bb in the brain or its associated tissues is unlikely to be 
due to a general increase in the permeability of the BBB. Importantly, our data does not 
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rule out the possibility that Bb could pass through the BBB via paracellular or 
transcellular routes using other mechanisms, for example ATP-dependent processes such 
as receptor mediated transport. 
 
3.4.2 Bb Localizes to Blood Vessels in the Dura 
Recently, it has been shown that the dura has functional primary lymphatic vessels that 
run parallel to the sagittal and transverse sinuses, and show the capacity to traffic 
lymphocytes from the meningeal compartment into the draining DCLNs (101).  Recent 
investigations have revealed that Bb can adhere to endothelial cells on the vessel walls 
by adhesion molecules using mechanisms similar to selectin-mediated rolling of 
leukocytes (256).  Seeking to identify where in the dura Bb may localize, we performed 
immunostaining on dura, gathered from perfused mice 45 dpi. We stained the samples 
with LYVE-1 and CD31, markers for lymphatic vessels and blood vessels, respectively. 
We observed Bb spirochetes in association with blood vessels, but not lymphatic vessels 
(Figure 3.1b-e, Figure 3.2c-f). We also observed Bb spirochetes in the lumen of a blood 
vessel, apparently adhering to the luminal wall (Figure 3.1c,d). These observations 
suggest that arterial or venous pathways may play a role the dissemination of Bb to and 
from the CNS. 
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Table 3. 1 Tissue culture. Summary results of Bb growth from dura, brain, and DCLN 
of Bb infected mice, after 12 days of culture 
Infection duration (days) 5 45 5 45 45 5 45 5
Tissue Dura Dura Brain Brain R-DCLN R-DCLN L-DCLN L-DCLN
Culture Positive Samples (3/7) (2/3) (2/5) (2/4) (2/3) (5/5) (2/3) (1/4)
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Table 3.2 Brain culture. Summary results of brain cultures from Bb-infected mice, checked daily for 12 
days. 
Infection 
Group
Sample 0 1 2 3 4 5 6 7 8 9 10 11 12
Final 
concentration 
on day 12 (/mL)
Sample 1 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) NA
Sample 2 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) NA
Sample 3 (-) (-) (-) (-) (+) (+) (+) (+) (+) (+) (+) (+) (+) 1.5x10^5
Sample 4 (-) (-) (-) (-) (+) (+) (+) (+) (+) (+) (+) (+) (+) 6.9x10^5
Sample 1 (-) (-) (-) (-) (+) (-) (-) (-) (+) (+) (+) (+) (+)(+) 4.38x10^5
Sample 2 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) NA
Sample 3 (-) (-) (-) (-) (-) (-) (-) (-) (+) (+) (+)(+) (+)(+) (+)(+)(+) 6.36x10^7
Sample 4 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) NA
Sample 5 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) NA
Days of culture
45dpi
5dpi
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Table 3.3 Dura culture. Summary results of dura cultures from Bb-infected mice, checked daily for 12 
days. 
Infection 
Group
Sample 0 1 2 3 4 5 6 7 8 9 10 11 12
Final 
concentration on 
day 12 (/mL)
Sample 1 (-) (-) (-) (-) (-) (-) (-) (-) (+) (+) (+) (+)(+) (+)(+) 1.16 x 10^6
Sample 2 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) NA
Sample 3 (-) (-) (-) (-) (-) (-) (+) (+) (+) (+)(+) (+)(+) (+)(+) (+)(+)(+) 2.03 x 10^7
Sample 1 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) NA
Sample 2 (-) (-) (-) (-) (-) (-) (-) (-) (+) (+) (+)(+) (+)(+) (+)(+) 5.8 x 10^5
Sample 3 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) NA
Sample 4 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) NA
Sample 5 (-) (-) (-) (-) (-) (-) (+) (+) (+) (-) (+)(+) (+)(+) (+)(+)(+) 1.85x10^7
Sample 6 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) NA
Sample 7 (-) (-) (-) (-) (-) (-) (-) (-) (+) (+) (+)(+) (+)(+) (+)(+)(+) 1.25x10^7
Days of culture
45dpi
5dpi
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Table 3.4 DCLN culture. Summary results of DCLN cultures from Bb-infected mice, checked daily for 
12 days. 
Infection 
Group
Sample 0 1 2 3 4 5 6 7 8 9 10 11 12
Final 
concentration on 
day 12 (/mL)
R-DCLN 1 (-) (-) (-) (-) (-) (-) (-) (+) (+) (+) (+)(+) (+)(+) (+)(+)(+) 8.6x10^6
R-DCLN 2 (-) (-) (-) (-) (-) (-) (-) (-) (+) (+)(+) (+)(+) (+)(+) (+)(+)(+) 8.1x10^6
R-DCLN 3 (-) (-) (-) (+) (+) (+) (+) (+) (+) (+) (-) (-) (-) NA
R-DCLN 1 (-) (-) (-) (-) (-) (-) (-) (-) (+) (+)(+) (+)(+) (+)(+)(+) (+)(+)(+) 1.38x10^7
R-DCLN 2 (-) (-) (-) (-) (-) (-) (-) (+) (+) (+) (+)(+) (+)(+) (+)(+)(+) 3.36x10^7
R-DCLN 3 (-) (-) (-) (-) (+) (+) (+) (+) (+) (+)(+) (+)(+)(+) (+)(+)(+) (+)(+)(+) 7.92x10^7
R-DCLN 4 (-) (-) (-) (-) (-) (-) (+) (+) (+) (+)(+) (+)(+)(+) (+)(+)(+) (+)(+)(+) 7.62x10^7
R-DCLN 5 (-) (-) (-) (-) (-) (-) (+) (+) (+) (+)(+) (+)(+)(+) (+)(+)(+) (+)(+)(+) 8.4x10^7
L-DCLN 1 (-) (-) (-) (-) (-) (-) (-) (+) (+) (+)(+) (+)(+) (+)(+)(+) (+)(+)(+) 2.7x10^7
L-DCLN 2 (-) (-) (-) (-) (-) (-) (-) (-) (+) (+)(+) (+)(+) (+)(+)(+) (+)(+)(+) 2.6x10^7
L-DCLN 3 (-) (-) (-) (-) (-) (-) (-) (-) (+) (+) (+) (-) (-) NA
L-DCLN 1 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) NA
L-DCLN 2 (-) (-) (-) (-) (+) (+) (+) (+)(+) (+)(+) (+)(+)(+) (+)(+)(+) (+)(+)(+) (+)(+)(+) 6.15x10^7
L-DCLN 3 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) NA
L-DCLN 4 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) NA
Days of culture
45dpi
45dpi
5dpi
5dpi
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Figure 3.1 Borrelia persistence in dura 45 dpi. (a) Spirochetes cultured from 45 dpi dura on day 12 of 
culture in BSK-II medium. Spirochetes stained with acridine orange for fluorescent visualization of 
Borrelia; n=3. (b) Representative image of superior sagittal sinus in dura whole-mount showing blood 
vessels (CD31, red), lymphatic endothelium (LYVE-1, yellow), and nucleated cells (DAPI, blue). Bb (Bb, 
green) were not detected in dural lymphatic endothelium; n=5 (c) Representative image of blood vessel in 
dura containing a Bb spirochete (Bb, green) adhering to a nucleated cell (DAPI, blue) on the endothelial 
layer (CD31, red); n=5; (d) Higher magnification image of (c) showing a Bb spirochete (Bb, green) 
adhering to nucleated (DAPI, blue) endothelial cell (CD31, red). (e) Spirochete (Bb, green) in association 
with blood vessel (CD31, red); images (c-e) correspond to n=5.          
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Figure 3. 2 Bb is culturable from 45 dpi dura and persists in association with blood vascular 
endothelium. (a) Bb spirochetes from 45 dpi dura on day 12 of culture in BSK-II medium; culture 
samples were fixed in paraformaldehyde and stained with Bb-specific primary antibody, followed by 
fluorochrome-conjugated secondary antibody; n=3; (b) Secondary antibody control of samples stained in 
(a); n=3; (c)Representative confocal image of Bb spirochete (Bb, green), in association with blood 
vascular endothelium (CD31, green); n=5; d, Y-Z projection of (c) demonstrating that Bb is located within 
blood vessel boundaries. (e/f) Secondary antibody controls for images presented in Fig 3.1b (e); n=1; and 
Fig 3.1c (f); n=1. 
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3.4.3 Elevated CD4+ T cells in the Brain During Early and Late-stage Infection 
In approximately 20% of neurological LD cases, post-infectious complications can arise 
in spite of antibiotic treatment, as can be the case in PTLDS. Manifestations of PTLDS 
can include fatigue, musculoskeletal pain, and cognitive abnormalities that vary in 
characteristics between individuals (29). Other post-infectious complications of LD, 
such as RLA, have been linked to specific T cell subsets (31,34). HLA subsets belonging 
to the HLA-DR isoform also appear to play a role in RLA, suggesting that in the context 
of LD, an immune response can influence the probability of developing post-infectious 
diseases, and that immunogenetics may play a role in LD autoimmunity (31, 257-259). 
Although it has not been demonstrated definitively, it has been suggested that PTLDS 
may also have autoimmune etiologies (29). To determine whether any 
immunophenotypic changes were apparent in our mouse model of neurological LD, we 
performed flow cytometry on cells isolated from the meningeal compartments or the 
brain, specifically probing for differences in the B cell and T cell subsets that may reside 
in these tissues pre- and post-infection (gating strategy is provided in Table 3.5, Fig 3.4, 
and Fig 3.5).
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Figure 3. 3 Infection by Bb does not alter BBB integrity.  (a) Mean fluorescent 
intensity of FITC-dextran signal per uL of plasma in naive mice that were either given 
no tracer (black bar), or  IV injection of  FITC-dextran (gray bar); n=3 naïve, n= 4 naïve 
+ dextran; ***p <0.001; (b) Mean fluorescent intensity of FITC-dextran signal per ug of 
brain  homogenate in naïve mice that were either given no tracer (black bar), or IV 
injection of FITC-dextran (gray bar); n=3 naïve, n=4 naïve + dextran; *p <0.05; (c) ratio 
of dextran mass in brain per dextran mass in plasma in mice that were injected with 
FITC-dextran and given sham infection for 5 days (black bar), or were infected by Bb 
297 for 5 days (gray bar); n=7 sham, n=4 Bb 297; n.s. is not significant. 
   
 
85 
 
 
Our data show that within 5 dpi there is a transient increase in conventional T cell-
dependent B2 type B cells (260) (CD45high, CD3-, CD19+, CD5+, CD1d-, IgDhigh), in the 
brain, and that the increase in these B cells coincides with an increase in CD4+ T cells in 
the brain (Figure 3.6 a-h). CD4+ T cells remained persistently elevated in the brains of 
Bb-infected mice as late as 45 dpi (Figure 3.6 e,f). These data suggest that a long-lasting 
subset of CD4+ T cells may respond to Bb infection in the CNS. Notably, we detected 
B1a (CD45high, CD3-, CD19+, CD5+, CD1d-), B1b (CD45high, CD3-, CD19+, CD5-, 
CD1d-, IgDlow), CD4+ (CD45high,CD3+,CD19-,CD4+), and CD8+ (CD45high, CD3+,CD19-
,CD8+) cells in both the brain and dura, in sham and Bb infected mice (Figure 3.7 a-h, 
Figure 3.8 a-f). We also detected B10 B cells (CD45high, CD3-, CD19+, CD5+, CD1d+), a 
unique B cell subset that has been shown to have anti-inflammatory function (261, 262). 
B10 B cells were only observed in the dura of Bb infected mice, at the 5 dpi time point 
(Figure 3.8 a,b). Collectively, these data support the emerging paradigm that the brain 
and meningeal compartments have a diverse repertoire of lymphocytes, and that this 
repertoire can change in response to Bb infection.    
 
3.4.4 IgG Detected in Brain During Late-stage Infection 
Immunoglobulins are not typically found in the brain or the CSF, due to the highly 
regulated tight-junction connections between endothelial cells that form the blood 
vessels of the BBB, and the ependymal cells that line the CP to form the blood-CSF-
barrier (94). When immunoglobulins are detected in the CSF, or the brain, they are 
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usually associated with neuropathologies, as is the case in multiple sclerosis, and 
alzheimer’s disease (263-266). Evidence suggests that antibodies directed against OspA, 
a common Bb antigen, can cross-react with neural peptides, leading to autoimmunity in 
PTLDS patients (122, 252). Because we detected B2 B cells and CD4+ T cells in the 
brains of Bb-infected mice (Fig 3.6 a,b,e,f), we expected that IgG could be present in the 
brain as well. Indeed, we observed deposition of IgG near the hippocampus and in the 3rd 
ventricle at 45 dpi, but not at 3 dpi, or in naïve mice (Fig 3.9 a-i). With the exception of 
the hippocampus (Fig 3.9 f) and 3rd ventricle (Fig 3.9 c), IgG was not detected in any 
other regions of the brain (Figure 3.9 i). We reason that IgG was not detected at 3 dpi 
(Fig 3.9 b,e,h), because sufficient time had not passed for seroconversion in response to 
Bb, as this can take as long as 4 weeks (267). Our observation that IgG accumulates in 
the brains of Bb-infected mice supports the possibility that B cells may contribute to the 
overall immune response during neuroborreliosis.  
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Table 3.5 Gating strategy. Flow cytometric gating strategy for T cell and B cell 
antibody panels that were used to stain brain and dural leukocytes.   
Panel
Antibodies in 
Panel
Subset Gating Strategy
Aqua
CD45
CD3
CD19
CD4
CD8
Aqua
CD45
CD3
CD19
CD5
CD1d
IgD B10
Singlet, Aqua-, CD45high, CD3-, 
CD19+, CD5+, CD1d+
Singlet, Aqua-, CD45high, CD3+, 
CD19-, CD4+, CD8-
Singlet, Aqua-, CD45high, CD3+, 
CD19-, CD4-, CD8+
Singlet, Aqua-, CD45high, CD3-, 
CD19+, CD5+, CD1d-
Singlet, Aqua-, CD45high, CD3-, 
CD19+, CD5-, IgDlow
Singlet, Aqua-, CD45high, CD3-, 
CD19+, CD5-, IgDhigh
B2
B cell
CD4
CD8
T cell
B1a
B1b
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Figure 3.4 Flow cytometric gating strategy for B cells in the dura and brain. (a-d) Flow cytometric gating strategy for B cells in the dura from 5 dpi 
sham (a), 5 dpi Bb (b), 45 dpi sham (c), and 45 dpi Bb (d); All samples were first gated on Singlets, then live cells were gated based on Aqua exclusion 
viability dye (data not shown). e-f, Flow cytometric gating strategy for B cells in the brain from 5 dpi sham (e), 5 dpi Bb (f), 45 dpi sham (g), and 45 dpi 
Bb (h); All samples were gated as described in table 3.5. All gating was done based on fluorescence minus one (FMO) controls (data not shown).   
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Figure 3.5 Flow cytometric gating strategy for T cells in the dura and brain. (a-d) Flow cytometric gating strategy for T cells in the dura from 5 dpi 
sham (a), 5 dpi Bb (b), 45 dpi sham (c), and 45 dpi Bb (d); All samples were first gated on Singlets, then live cells were gated based on Aqua exclusion 
viability dye (data not shown). (e-f) Flow cytometric gating strategy for T cells in the brain from 5 dpi sham (e), 5 dpi Bb (f), 45 dpi sham (g), and 45 
dpi Bb (h); All samples were gated as described in table 3.5. All gating was done based on fluorescence minus one (FMO) controls (data not shown). 
   
 
90 
 
 
  
Figure 3.6 B2 B cells and CD4+ T cells in brain and dura. (a/b) Percent (a) and total number (b) of B2 B cells in the brain; 
Treatment groups had the following n values for brain samples: 5 dpi Sham n=4, 5 dpi Bb n=3, 45 dpi Sham n=5, 45 dpi Bb n=5; 
(c/d) Percent (c) and total number (d) of B2 B cells in the dura; Dura samples had the following n values: 5 dpi Sham n=5, 5 dpi Bb 
n=4, 45 dpi Sham n=5, 45 dpi Bb n=5;  (e/f), Percent (e) and total number (f) of CD4+ T cells in brain; Treatment groups had n-
values as described for (a/b); (g/h) Percent (g), and total number (h) of CD4+ T cells in dura; Treatment groups had n-values as 
described for (c/d). All data are representative of two independent experiments. Sham infection is represented by black bar, Bb 
infection is represented by gray bar; N.D. is not detected; * P <0.05; ** P <0.01, n.s is not significant; 2-way ANOVA w/ Holmes-
Sidak correction for multiple comparisons; Error bars represent standard deviation 
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3.4.5 Behavioral Deficits During Late-stage Infection  
Patients with neuroborreliosis infection, and some patients with PTLDS, can develop 
cognitive abnormalities. Magnetic resonance imaging and pathology reports from patient 
tissues demonstrate that deficits in cognition may be associated with encephalopathy or 
encephalomyelitis (23, 123). Typical cognitive abnormalities include difficulty with 
verbal fluency, impaired short-term memory, and generally impaired ability to process 
information. These cognitive deficits are usually accompanied by fatigue, sleep 
disturbances, and depressed mood (123). To date, we have not identified any studies that 
have investigated behavioral changes in Bb infected mice. Thus, we sought to evaluate 
basic changes in nociception, movement/mobility, and visual memory in our model of 
neurological LD. To test these parameters, we utilized the Von Frey pain test, OF 
testing, and the NORT test (Figure 3.10 a-d, Figure 3.11). Based on the Von Frey pain 
test, Bb infected mice required less stimulus to induce a hind-leg withdrawal response 
(Figure 3.10a), suggesting increased nociception in the periphery, a phenomenon that is 
consistent with clinical manifestations of neuropathy in patients (124). The OF test 
revealed that Bb infected mice were in a “high mobility state”, as defined by a rotational 
displacement of the body that resulted in >25% surface area displacement, less often 
than sham-infected controls. In total, the Bb infected animals spent less cumulative time 
in the high mobility state (Figure 3.10 b).
   
 
92 
 
 
Figure 3.7 IgG deposition in the brain and ventricles during late-stage Bb infection. 
Epifluorescent images of brain sections from the (a-c) ventricular hippocampal 
commisure, (d-f) dentate gyrus, or (g-i) cortex, in mice that were (a,d,g) naïve, (b,e,h) 
infected by Bb for 3 days, or (c,f,i) infected by Bb for 45 days. Cells were stained with 
DAPI nuclear stain (blue), or IgG (orange); n=1 per group.
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With respect to movement, Bb infected mice travelled less total distance, and had a 
lower average velocity when moving than sham controls (Figure 3.10 c). Surprisingly, 
neither groups demonstrated any differences in their ability to discern novel objects, as 
measured by the discrimination index, and recognition index (124) (Figure 3.10 d). The 
behavioral testing that we performed demonstrates that, in our mouse model, long-term 
Bb infection can result in increased nociception, and decreased mobility/movement 
activity. Importantly, our negative result in the NORT does not rule out the possibility 
that other cognitive abnormalities exist. 
 
3.5 Discussion  
We have used a CSF-tropic strain of Bb that is common in the United States to induce 
intradermal Bb infection in an LD-susceptible mouse strain. Within 45 dpi, CNS tissues 
and  associated lymph nodes were culture positive for Bb. Confocal imaging 
demonstrated that Bb spirochetes in the dura had a tendency to localize near or in blood 
vessels, but not lymphatic vessels, suggesting a possible preference for blood borne 
dissemination into the CNS.  We observed that a low frequency of B and T lymphocytes 
were detectable in the brain and dura of infected and control mice. In particular, CD4+ T 
cells in the brain increased in frequency and total number during early infection, and 
they persisted as late as 45 dpi, suggesting that CD4+ T cells may play a long-term role 
in Bb immunity in the brain. Behavioral testing demonstrated that, similar to patients, 
mice that were infected long-term by Bb exhibited decreased threshold to pain, impaired 
mobility, and decreased movement. Collectively these observations suggest that our 
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mouse model may be appropriate for understanding the etiologies that underlie LD and 
its associated neuroimmunological complications
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Figure 3.8 Behavioral changes in Bb-infected mice 45 dpi. (a) Changes in nociceptive 
response to Von Frey filaments in Bb vs Sham treated mice at 45 dpi; Each data point 
represents the withdrawal response from each of two hind-legs; All mice were tested as 
described in methods, and the Von Frey test was repeated two times for each group of 
n=5; (b) OF results of Bb infection-induced changes in number of highly mobile 
occurrences (left), and cumulative duration of time spent in highly mobile state (right); 
mobility threshold is defined as >25% displacement per second, as described in methods; 
n=4 animals per group ; (c) OF results of Bb infection-induced changes in total distance 
travelled (left), and mean velocity (right); n=4 animals per group; (d) NORT results 
quantifying changes in discrimination index (left) and recognition index (right); n=4 
animals per treatment group; * P <0.05, **** P <0.0001, n.s. not significant, two-tailed 
unpaired t-test. Error bars represent standard deviation. 
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Figure 3.9 Schematic diagram of OF testing and NORT.  (a) Habituation phase of OF 
testing, lasting 10 minutes, followed by a 90 minute rest interval; (b) Training phase of 
NORT with two identical objects, lasting 5 minutes, followed by a 90 minute rest 
interval; (c) Testing phase of NORT with one familiar object (pink circle A) and one 
novel object (tan square B), lasting 5 minutes. 
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4. SUMMARY 
 
4.1 LD and its Post-infectious Complications 
LD has a growing incidence in the United States, and Bbsl pathogens are emerging that 
can cause zoonotic infection, and may be infectious in humans (1-4, 6, 7). The myriad of 
symptoms that can arise after acute Bb infection provide evidence that Bb affects human 
physiology on a multisystem level. Although many individuals may recover from the 
symptoms that result from Bb infection, up to 20% of individuals that receive antibiotic 
treatment after late-stage disseminated infection do not find relief from their symptoms, 
resulting in RLA and/or PTLDS (29, 268, 269).  
 
As we have described in detail, RLA is primarily characterized by persistent pain and 
joint inflammation, despite antibiotic therapy after Bb infection (31). Evidence suggests 
that TLR2 receptors and antigen presentation machinery belonging to the HLA-DR 
group play a role in responding to Bb infection, and some alleles or polymorphisms of 
these molecules are associated with increased probability of developing RLA (141, 142). 
Specifically, RLA is associated with HLA-DRB1 and HLA-DRB5 alleles, and at least 
one polymorphism (Arg753Gln) in the TLR-2 receptor.  T cells and DCs appear to 
facilitate and support RLA through non-classical antigen presentation via CD1 group 1 
(CD1a-c) molecules, and Fas:FasL interactions (109, 141, 142, 145). CD1a-c molecules 
are regulated by IL-1, which depends on cleavage induced activation by caspase-1. The 
combination of caspase-1 activity, and IL-1 production influence expression of CD1a-
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c, and associated Bb antigen presentation via CD1a-c to CD1a-c ligands, that may 
include the  TCR (109). FasL expression by  T cells is primarily influenced by 
CD4+ T cell-secreted IL-2, a molecule that also upregulates CD25 on  T cells (105). 
The combination of two-way signaling between γδ T cells and DCs results in the 
production of proinflammatory cytokines that include IL-6, IL-12, IFN-, TNF-, and 
IL-17 (108) (Fig 2.3). Ultimately, the  T cell response to Bb induces inflammation, 
presumably to clear Bb infection. In the case of RLA, it seems that the response to Bb 
infection is long-lasting, resulting in autoimmunity. The impetus for long-lasting 
immune responses may include persistent infection and/or permanently aberrant immune 
alterations due to the initial response to Bb infection, based on immunogenetics.          
 
Like RLA, PTLDS is a post-infectious complication of LD that is thought to have 
autoimmune etiologies (122, 252, 253). Although patients with PTLDS can also exhibit 
symptoms of RLA, PTLDS includes persistent neurologic, neuropsychiatric, and 
neurocognitive deficits (23, 26, 29, 123, 270). The precise etiology of PTLDS is 
unknown, and to date, there are no FDA approved drugs for the treatment of PTLDS. 
The paucity of information about PTLDS is partly due to its relatively recent recognition 
as a legitimate syndrome (270), and the absence of an animal model. Typically, RMs 
have been used to model neurological LD in an experimental setting, but because of the 
high cost and relatively slow reproductive rate of RMs, our knowledge of the 
mechanisms that Bb utilizes to cause or facilitate neurological LD is especially limited. 
A mouse model of neuroborreliosis would be particularly useful, because it would allow 
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investigators to perform studies that could elucidate the pathogenic mechanisms that Bb 
utilizes to establish neuroborreliosis, without necessitating the use of the cost-prohibitive 
RM. Another advantage of a mouse model of neuroborreliosis, is that it could provide a 
test model for inducing PTLDS, and understanding its underlying etiologies. A single 
mouse model of neuroborreliosis was previously published, however the approach for 
establishing infection relied on intracerebroventricular inoculation of Bb into the CSF, 
and was therefore questionable with respect to the natural mechanism of pathogenesis 
(110). The natural route of infection is through a tick bite, which could not penetrate the 
skull, or the ventricles of the brain. It remains unclear why previous investigators did not 
use Bb 297 to induce CNS infection via the intradermal route. Perhaps they did and were 
unsuccessful. Overall, the mouse model of neuroborreliosis that we developed in the 
experiments that we described above, is the first mouse model of neuroborreliosis that 
replicates Bb infection of the CNS using an approach that has relevance to the natural 
vector.    
 
4.2 Persistent Bb Infection in the Dura and Brain  
For the first time, we have demonstrated that a common North American strain of Bb, 
Bb 297, is capable of establishing infection as early as 5 dpi and persisting in the CNS of 
a mouse as late as 45 days after intradermal infection (Figure 3.1 a-e, Fig 3.2 a-f, Table 
3.1 – Table 3.4). These observations bring into question whether similar mechanisms 
may be at play in humans that have neurological LD, or PTLDS. In our experiments, 
most of the Bb that we observed in the dura were in the dural blood vessels (Figure 3.1 
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d,e, Figure 3.2 c,d) or the dural cortex (not shown), but not in the lymphatic vessels of 
the dura (Figure 3.1b). In every case, when we observed Bb adhering to blood vessels in 
the dura, the vessel diameter was always less than 100um (Figure 3.1 c). In mice, arteries 
and veins can range in diameter, depending on their location, and function, ranging from 
~100um to ~2mm. Arterioles and venules, the next lowest hierarchy of blood vessels, are 
typically between 30um-100um in diameter, and at the capillary level, the luminal 
diameter is just large enough for erythrocytes to travel through, approximating 8-10 um. 
Although there are many differences between arterial and venous blood vessels, with 
respect to our studies, the most important difference is that veins and venules have much 
lower pressure than arteries or arterioles, and consequently the vessel walls experience 
lower sheer forces, thus providing better anchoring points for pathogens. Also, venules 
that begin immediately after capillaries, called post-capillary venules, are much more 
permeable than arterioles, and they are well described sites where leukocytes can roll, 
adhere, and extravasate into peripheral tissues (271-273). In other studies, it has been 
shown convincingly that Bb has a tendency to adhere to and extravasate through post-
capillary venules in the periphery (256, 274). Because we did not observe spirochetes in 
any blood vessels that were large enough to be considered arteries or veins, arterioles or 
venules were the only candidates that could explain which type of blood vessels Bb had 
a tendency to adhere to (Figure 3.1, Figure 3.2). Although we did not perform any 
immunostaining that could distinguish between arterial or venous blood vessels, of the 
remaining candidates, the most logical and likely candidates are post-capillary venules, 
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because of their well-characterized function in supporting leukocyte and Bb 
adherence/extravasation into tissues.  
 
We were surprised that Bb was not detected in any of the lymphatics in the dura, because 
others have provided indirect evidence that Bb disseminates and infects lymph nodes in 
a pattern that is consistent with the directionality of lymphatic flow (78), suggesting to 
us that Bb may disseminate through the lymphatic system. Contrary to our expectations, 
in our model, Bb was not observed in the lymphatics of the dura. Instead, it was apparent 
that Bb had a tendency to associate with blood vessels in the dura. There are a few 
possible explanations for the absence of Bb in the dural lymphatic vasculature. First, in 
the studies where Bb was indirectly shown to disseminate through the lymphatic 
vasculature, the strain of Bb used was strain N40, a strain that has been shown to induce 
lymphoadenopathy (78). In our model, we used Bb strain 297, a strain that was 
originally isolated from the CSF of a patient in New York (111). Importantly, in our 
experiments, unlike the group that used strain N40, we injected Bb in the dorsal thoracic 
midline, a region where multiple lymphatic drainage routes exist. Baumgarth et al 
administered Bb infection in the foot pad, an anatomical location where there is a single 
lymphatic pathway from the infection site to the downstream lymph nodes (78). Thus, 
although our data demonstrate that Bb may utilize multiple pathways for dissemination, 
they also don’t reject the validity of the observations reported by Baumgarth et al (78), 
because we used fundamentally different approaches to induce infection. It is also 
possible that strain 297 may utilize different mechanisms for establishing pathogenesis 
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than strain N40, and these mechanisms may contribute to the different phenotypes that 
can manifest, for example, the lymphoadenopathy that is observed in response to 
infection by strain N40 versus CNS infection that is observed after infection by strain 
297. Furthermore, the results with strain N40 were obtained using C57/BL6 mice that 
have substantially different immunogenetics than C3H/HeN mice that were used in our 
studies. Thus, in our model, the absence of Bb in the lymphatic vessels could be due to 
strain dependent differences either in Bb or the strain of mouse used. Another important 
possibility is that in our studies Bb may have originally disseminated into the dura by 
way of transmigration from the CSF through the dural lymphatics, and that at the later 
time points when we performed immunostaining and imaging, the Bb had migrated 
through the dural cortex toward dural blood vessels. Although this is possible, it seems 
unlikely that Bb would migrate toward and into blood vessels, because blood carries 
IgM antibodies that can destroy Bb after the onset of adaptive immunity to Bb infection 
(typically less than 1 week) (275). A much more plausible explanation is that Bb 
disseminated through the blood, not the lymphatics, because of the relative directionality 
of blood and lymph flow in the dura. Although our current understanding of lymph flow 
directionality in the dura is incomplete, all existing studies show that the dural lymphatic 
vessels transport some portion of interstitial fluid and CSF out of the CNS downstream 
into the DCLNs (101). If this is true, then Bb would be most likely to disseminate from 
the blood into the cortex of the dura, and then remain in the cortex thus evading 
clearance by high molecular weight antibodies such as IgM. The latter explanation 
would be most consistent with our results.  
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With respect to our investigation of the brain, similar to our results in the dura, we 
observed that infection with Bb 297 resulted in culture positivity at 5dpi and 45dpi. At 
both time points, however, less than half of the tissues were culture positive (Table 3.1). 
The phenomenon that bacteria can be viable, but not culturable (VBNC) has been 
explored in detail in multiple pathogens (276-278). In the case of Bb, an emerging body 
of evidence suggests that unculturable spirochetes may be in an altered metabolic state 
that is characterized by low production of ATP, a metabolic state that is commonly 
observed in Bb spirochetes that colonize the mid-gut of unfed/unengorged ticks (5). 
Remarkably, Bb spirochetes that are in stationary phase seem to have phenotypic 
differences that allow them to persist in spite of multiple antibiotic treatments, possibly 
due to alterations in their metabolic profiles (279, 280). In our experiments, we did not 
have evidence that any spirochetes were present in the culture negative brains, however, 
the presence of metabolically-altered, VBNC Bb, represents a likely possibility that may 
reconcile the differences that we saw within groups of mice that were infected with Bb. 
 
We are also interested in determining where in the brain Bb may reside. Although our 
experiments demonstrated that Bb is culturable, and therefore resides somewhere in the 
brain, we do not have sufficient evidence to determine the anatomical location that Bb 
may be establishing infection in the brain. There are at least 9, non-exclusive 
possibilities that describe where Bb could be persisting in the brain. Bb may be 1) in the 
brain parenchyma, 2) adhering to the blood vessels that comprise the BBB, 3) Adhering 
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to the perivascular Virchow-Robin spaces between the blood vessels and the 
parenchyma, 4) adhering to ependymal cells of the CP, 5) adhering to blood vessels that 
supply the CP, 6) Floating freely in the CSF, 7) in the pia mater or the vessels that 
supply the pia mater (we did not remove the pia before culturing brains), 8) inside any of 
the cells that form the substructures of the brain described above (ie intracellular 
infection), 9) Any series of permutations resulting from options 1-8. Based on the 
number of possibilities described above, it is clearly out of the scope of this study to 
address these questions, however, future studies may be directed to this end. 
Speculatively, we predict that at least one of these possibilities is accurate, and that it is 
likely that more than one of these possibilities happen simultaneously. Specifically, we 
are in favor of options 3-6, for the reasons described below.  
 
The blood vessels that supply the choroid plexus do not have the same tightly regulated 
barrier function as the BBB, and as a result, interstitial fluids freely leave the capillary 
beds and circulate into the perivascular spaces of the CP (94). The Ependymal cells that 
line the CP are connected by tight junctions, and with the aid of ion and aquaporin 
channels, they selectively regulate which components of interstitial fluids can travel 
through the basolateral surface of the blood-CSF barrier, into the CSF (95). We suggest 
that the relative permeability of the blood vessels that supply the CP, makes them good 
targets for Bb to adhere to, and/or extravasate through. Much like the dura, where we 
have demonstrated that spirochetes can persist, ependymal cells express collagen, and 
the surrounding matrix contains decorin, both proteins that Bb has tropisms for (118, 
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281). If Bb spirochetes can access ependymal cells by extravasating through the blood 
vessels of the CP, this is another area where the microenvironment seems suitable for Bb 
to persist. From there, Bb could either end its route of dissemination, or it could continue 
on through the brain. If it continued through the brain, it would have to get through the 
blood-CSF barrier that is regulated by ependymal cells of the CP. Bb could compromise 
the blood-CSF barrier by receptor mediated endocytosis (transcellular), or it could 
compromise the barrier by going around ependymal cells and degrading the CP 
(paracellular). If Bb utilized receptor-mediated pathways, we would expect to see Bb 
circulating in the CSF. If tight-junction proteins were degraded, we would still expect to 
see Bb in the CSF, but we would also expect that inappropriate constituents of the 
interstitial fluid would diffuse into the CSF, and therefore be detectable. Finally, if Bb 
entered the CSF it would almost definitely be in Virchow-Robin spaces of the 
parenchyma, because CSF circulates through these spaces as part of its function to clear 
interstitial fluids (94). Collectively, the theoretical mechanism described above, 
corresponds to the aforementioned possibilities 3-6.  Because we have optimized the 
immunostaining protocol for imaging Bb and blood vessels in the dura, we are confident 
that we can use similar protocols to immunostain Bb in the brain, thus providing 
information about anatomical localization, and mechanisms that Bb may utilize to infect 
the CNS. Also, because CSF can be sampled, we should theoretically be able to 
determine whether Bb penetrated the blood-CSF barrier by transcellular (CSF 
constituents relatively unaltered), or paracellular (CSF constituents altered) routes. We 
will likely address these questions in the near future.  
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We were surprised to observe differences in culture positivity of the R-DCLN and L-
DCLN at the 5 dpi time point (Table 3.1). Our assumptions going into the experiments 
were that CSF drainage into downstream peripheral lymph nodes, whether coming from 
the dural lymphatics or the cribiform plate or both, would be distributed without overt 
preference for a particular DCLN. After all, in the mouse, the R-DCLN and L-DCLN are 
within millimeters of each other, a relatively short distance for lymph to travel. The 
observation that all R-DCLN were culture positive, yet only 1/4 of L-DCLN were 
positive, suggests that there may something unique about how Bb disseminates from the 
infection site in the dorsal thoracic midline. We think there are at least two possible 
explanations for this observed phenomenon. First, it may be the case that the lymphatic 
vessels at the site of infection drain lymph in such a way that lymph resistance is lowest 
in the direction of the R-DCLN. Differences in lymph pressures within the lymphatic 
vessels could be achieved by selective shunting mechanisms at the level of the L-DCLN, 
or the afferent vessels upstream of it. In parallel, resistance in the lymphatic vessels 
leading to the R-DCLN could be reduced by any combination of mechanisms that 
regulate dilation of the afferent vessels upstream of the R-DCLN. Second, it may be the 
case that Bb disseminates into the CNS independent of lymph drainage at the infection 
site, and that once in the CSF, selective lymph drainage mechanisms via the cribiform 
plate or the dural lymphatics direct CSF drainage toward the R-DCLN. Because the 
lymph axis between the CSF and the DCLN is still not well-understood, there are likely 
other mechanisms, yet to be discovered, that may explain the phenomenon that we 
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observed. Importantly, our data suggest that with respect DCLNs, Bb does not 
disseminate through the blood, because if it did, there would be no differences in Bb 
culture positivity between the R-DCLN, or the L-DCLN, and as we have shown, this is 
clearly not the case.  
 
4.3 Neuroimmunology of LD   
The emerging paradigm in neuroimmunology is that the CNS is not necessarily immune 
privileged. In fact, it has been shown that lymphocytes are present in the dura, and can 
accumulate in the dural lymphatics, if the draining DCLNs are ligated (101). Consistent 
with this emerging paradigm, we have identified multiple subsets of B cells and T cells, 
albeit few in number, in the brain and dura under conditions of sham treatment with 
BSK-II medium or Bb infection (Figure 3.5a-f, Figure 3.6a-g ). Strikingly, we observed 
an initial increase in the number and frequency of CD4+ T cells in the brain during early 
infection with Bb, and CD4+ T cell populations remained elevated in the brain as late as 
45 dpi (Figure 3.5d). We also observed an increase in T cell dependent B2 B cells in the 
brain at 5 dpi, but the differences between Sham and Bb infection were not significant at 
45 dpi (Figure 3.5b). This observation is consistent with reports that Bb tends to promote 
T cell-independent antibody production, a B cell function that is not supported by B2 B 
cells (78, 86). Thus, it is possible that B2 B cells that were observed at 5 dpi did not 
receive the signals necessary for survival, that they migrated to other secondary immune 
organs such as the lymph nodes, or that they moved to ectopic germinal centers. Another 
distinct possibility is that the B cells observed in the brain at 5 dpi, became activated and 
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changed the surface expression of their phenotypic markers. For example, if B2 B cells 
became activated by a subset of CD4+ T cells, they would ultimately mature into 
MHCII-, CD138+ plasma cells that produced IgG antibody (282). Although we did not 
test for CD138 as a surface marker, the data that we obtained from our immunoglobulin 
experiments in the brain (Figure 3.8a-i) demonstrate that in the CP and in certain areas 
of the hippocampus, there is a substantial increase in IgG at 45 dpi, that is not observed 
at 5 dpi. It is not surprising that IgG was undetectable at 5 dpi, because 5 dpi would be 
too soon for the mouse to seroconvert from IgM to a Bb-specific IgG response, as this 
can take up to 4 weeks (267). Thus, implicit in our results, is the indication that the IgG 
observed in the brain at 45 dpi was specific to Bb infection. The overall 
neuroimmunological picture demonstrates that persistent Bb infection in the brain 
induces a measurable neuroimmune response that is characterized by CD4+ T cells, B2 
B cells, and IgG antibody in the brain. We are interested to know whether any Th1 or 
Th17 associated cytokines are produced by CD4+ T cells that were detected in the brains 
of Bb infected mice, at both of the time points that we tested.  
 
B1 B cells represent a distinct subset of natural IgM secreting cells that come from a 
different cell lineage than conventional B2 B cells.  B1 cells are subdivided into two 
subclasses, based on CD5 expression. The CD5+ group called B1a is generated early in 
life, and the CD5- group, called B1b arrives later than B1a and can increase in response 
to infection. The majority of IgM that is produced by B1a seems to be “natural antibody” 
that serves two functions. The first function of B1a-secreted natural antibody is to 
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opsonize pathogens either specifically, or non-specifically (283, 284). The second 
function of natural antibody is to bind self-antigens that are displayed by abnormal, 
injured, or dying cells, a function that is thought to fulfill a role in housekeeping, by 
marking unwanted cells for destruction (285). In contrast, the B1b subset seems to be 
primarily involved in T-independent IgM production of specific antibody against 
bacterial pathogens that include Borrelia hermsii, a relapsing fever spirochete that is 
related to Bb (286). Generally speaking, B1 cells originate in the fetal liver or bone 
marrow and rest in either the lymphoid tissues such as the spleen or lymph nodes, or 
they move to body cavities such as the peritoneum or pleural spaces where they function 
as memory B cells (287). Prior to our investigation, the role of B1 cells has not been 
explored in neuroborreliosis, however, there is a growing body of evidence that B1 cells 
are present in the brain during neurologic disorders, although their roles are not well 
understood. For example, in a mouse model of MS, called EAE, depletion of B1a cells 
after disease onset decreased demyelination, but depletion of B1a during the induction 
phase of EAE increased the incidence of EAE (288), suggesting that the timing and 
duration of a B1a response may determine whether it is helpful, or harmful to the 
individual. To date, there have not been any reports of B1b cells in the CNS.   
Whether the B1 cells that we observed in our model play a role in the outcome or 
progression of neuroborreliosis remains to be determined. Because, B1s predominantly 
produce IgM in response to pathogens, we would expect that if they had a role in 
responding to neuroborreliosis, IgM would be detectable somewhere in the CNS. 
Identifying the exact anatomical location of B1 cells within the CNS would help us to 
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determine where to look for IgM, and to design behavioral or neurophysiological 
experiments to assess what role(s) B1 cells or their associated immunoglobulins may 
have in response to Bb infection. Answering these questions could elucidate mechanisms 
specific to the neuroimmune response to Bb, or other related infections of the CNS that 
are implicated in autoimmunity.    
 
We were surprised that there was a subset of B10 B cells that were that were detected 
transiently in the dura of Bb infected mice at 5 dpi (Figure 3.6g). B10 B cells have not 
previously been reported in the CNS, however, in other tissues they have been shown to 
have anti-inflammatory / immune suppressive function that is mediated by the secretion 
of IL-10 (261, 262). Although we did not specifically test for the production of IL-10 in 
the dura, the phenotypic surface markers of B10 (CD45high, CD3-, CD19+, CD5+, CD1d+) 
were present. Assuming that the presence of B10 B cells in the dura was not irrelevant, 
we hypothesize that they may be part of a normal response to CNS infection, designed to 
limit the magnitude of inflammation that can occur in the CNS, thus providing a failsafe 
that inhibits inflammation-induced damage in response to infection. The other possibility 
is that B10 B cells are not part of a normal immune response to CNS infection, and that 
Bb subverts the immune system by activating B10 B cells, reducing inflammation, and 
consequently surviving in the niche environment of the dura. Loss or gain of function 
studies revolving around the respective absence or upregulation of B10 B cells would be 
helpful in clarifying the role that they may play in response to CNS infection by Bb or 
other CNS-tropic pathogens.  
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4.4 Altered Behavior 
The behavioral experiments that we performed in Bb-infected mice were among the first 
behavioral studies in experimental LD infection. We expected that mice infected with Bb 
297 for 45 days would display some of the behavioral deficits that are present in humans 
that have LD, such as musculoskeletal pain and peripheral neuropathy, as well as 
changes in cognition (23, 123, 289). We hypothesized that Bb infected mice would 
exhibit a decreased pain threshold, deficits in tasks related to motor function, increased 
anxiety behaviors, and impairment in long-term memory. Consistent with our 
expectations, Bb-infected mice showed increased nociception (decreased pain threshold) 
to external stimuli in the rear hind-paw, as determined by the Von Frey test (Figure 
3.7a). Although the differences in the pain response only varied by one step size in the 
weight of the Von Frey filament, they were nonetheless statistically significant and 
consistent with the results of other behavioral tests that we performed.  
 
The OF test serves as a general screening parameter for changes in movement, mobility, 
and anxiety behaviors (126, 127). Anxiety behavior is usually assessed by changes in 
exploratory behavior in the new cage, specifically total distance travelled over a period 
of time (290). There are two factors that can be a stimulus for anxiety in the OF test, 1) 
social isolation that results from physical separation from littermates, and 2) the stress 
caused by a brightly lit, novel environment (290-292). We expected that all three 
parameters, movement, mobility, and anxiety, would be altered in Bb-infected mice. Our 
results from the OF test demonstrated that Bb-infected mice exhibited overall decreases 
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in mobility relative to sham controls, as defined by the frequency (number of high 
mobility events that occurred), and cumulative duration of the highly mobile events 
(Figure 3.7b, also see methods, section 3.2). We also observed that Bb-infected mice 
moved with a slower average velocity, and that the total distance travelled was relatively 
less than sham controls (Figure 3.7c). Collectively, the OF data demonstrate that there 
are unequivocal differences in mobility and movement, however the interpretation of 
anxiety behavior is less clear. Although anxiety behavior is typically quantified by 
exploration and total distance travelled, the results that we obtained could be confounded 
by general increases in peripheral neuropathy and nociception, as we observed in the 
Von Frey test (Figure 3.7a). It is possible that Bb-infected mice travelled slower, and 
thus explored the cage less because of increased musculoskeletal or joint pain in the 
periphery. Another possibility is that the mice had anxiety in addition to peripheral pain. 
The limitation of our approach is that we were not able to definitively determine whether 
anxiety played a role in the results of the OF test, and this is something that should be 
addressed moving forward, possibly by implementing different behavioral tests.  
 
The purpose of the NORT test, was to determine whether Bb-infected mice experienced 
changes in visual memory impairment. The principle of the test is that mice with intact 
memory will spend more time exploring a novel object, than an object that is otherwise 
familiar (293). We expected that Bb-infected mice would show some impairment in their 
ability to discern the novel object from the familiar object, presumably due to Bb-related 
cognitive deficits in visual memory. Our results demonstrated that Bb-infected mice 
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showed no differences in their preference for a novel object, as compared to sham 
controls (Figure 3.7d). Preference for the novel object was measured by the 
discrimination index, and recognition index, as described (293). A major challenge in 
designing NORT experiments is determining the resting interval between the training 
period, when mice spend time with two identical objects, and the testing period, when 
mice are re-exposed to the familiar object from the training period in addition to a novel 
object. We chose a resting interval of 90 minutes because this retention period is 
relatively long, and corresponds to brain function related to the hippocampus, whereas a 
short resting interval would measure function related to the perirhinal cortex (293-295). 
We hypothesized that the hippocampus was the more likely target of Bb-related 
inflammation because the hippocampus if often affected in tertiary syphilis, an infection 
caused by a spirochete that is a close cousin of Bb, Treponema pallidum (296), and 
because we observed IgG deposition in the areas near the hippocampus of Bb infected 
mice (Figure 3.9 c,f). Although our results demonstrated no differences in visual 
memory between Bb-infected mice and sham controls, we cannot rule out the possibility 
that shorter, or longer retention intervals would produce different results. Furthermore, 
the NORT is simply one measure of memory, and it does not assess changes in other 
memory-related parameters such in spatial or visuospatial memory. Other tests that may 
be appropriate for testing spatial or visuospatial memory would include the Morris water 
maze, or the novel object location test (NOLT), respectively (297, 298). 
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4.5 Limitations of This Study 
One of the inherent challenges of culturing tissues ex-vivo is preventing contamination 
of the tissues by common microbes that may be in the lab. This is especially difficult 
when the tissues are coming from organisms that have abundant commensal biota within 
and around many of their cavities, that under normal circumstances the immune system 
prevents from growing. It is practically impossible to keep these tissues sterile, so the 
next best approach is to use aseptic technique, and this is the approach that we used. In 
our experience, out of 5 tissues harvested, anywhere from 0-2 samples would become 
contaminated upon culture for spirochetes. Contamination was evident based on dark 
field microscopic visualization of bacteria with cocci or bacilli morphology. When 
contamination was observed, the samples were omitted from the study, and this is why 
the total n-values for each tissue vary (Table 3.1). We are not aware of alternative 
approaches that would reduce the probability of contaminating samples without 
introducing lurking variables, thus occasional contamination may simply be an 
acceptable limitation of our approach.     
 
The immunoglobulin data that we presented (Figure 3.9 a-i) suggests that IgG may 
accumulate in the brains of Bb infected mice, at 45 dpi. The main limitation of these 
experiments is that each group had an n=1. Although the differences in IgG deposition 
between Bb infection at 45 dpi, and Bb infection at 5 dpi are substantial, if we are to 
state the data conclusively, the experiments will need to be replicated with higher n-
values, and perhaps quantified by analytical imaging software such as ImageJ.  It is also 
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important to note that at the time the experiments were performed, although we did 
serum block the tissues, we did not Fc block prior to immunostaining. It is unlikely that 
omitting the Fc blocking step would result in such a substantial difference in 
immunostaining, however, it is still an important control that will be necessarily in 
maintaining the rigor of our experiments, thus giving us greater confidence in the 
conclusions that we draw. 
 
A typical question and criticism that we have received from peers is “why hasn’t anyone 
else been able to establish this model?” It is a good question, because for many years 
independent efforts to establish a mouse model of neuroborreliosis have been 
unsuccessful. It is difficult to know why others were not successful in developing the 
model, because their approaches were not published, so it is not really possible to assess 
or criticize their methodology. What we have observed is that in the literature, 
investigators rarely use Bb 297, but often use Bb B31. We reasoned that this could 
possibly account for the difference between the results that we obtained, and the 
negative results that others obtained. Based on our assessment using immunostaining, 
neither B31 Bb, nor a GFP variant of B31 Bb resulted in infection in the brain, or its 
associated perivascular / periventricular tissues (data not shown). A limitation in our 
approach was that we did not attempt to culture the brains of B31-infected animals. 
Although we think that our immunostaining approach would have revealed Bb infection 
in the brain, we would be more confident in our conclusions if we had cultured the brain, 
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dura, and DCLNs of B31 infected animals, as we did for 297 infection. Currently we are 
performing experiments to address this limitation.      
 
We used a tracer-based assay with 10KD FITC-Dextran to determine whether the BBB 
was compromised (Figure 3.3 a-c). Based on our results, it was evident that there were 
no differences in tracer signal between mice infected with Bb 297 and sham treated 
mice. Although there was little variability in this data, and the n-values were appropriate, 
we are concerned that the methodology that we used may have diluted an already low 
signal. The methods relied on tissue homogenization, formamide-based tracer extraction, 
and multiple rounds of centrifugation and removal of supernatant. This methodology 
would likely be appropriate for circumstances where there is a significant breach in the 
BBB, for example traumatic brain injury, or ischemic stroke, but it is unclear how 
sensitive this approach was. A better approach may have been to use intravital 
microscopy to assess the diffusion of tracer through brain or pial vessels of interest in 
real time. Indeed, we did consider the intravital approach, but we were initially restricted 
in our resources, and although we did eventually obtain funding to purchase the 
necessary equipment, the bureaucratic hierarchy of decision making delayed our 
acquisition of the equipment until the funding expired. For us, this was a seminal lesson 
on diseconomies of scale, and the major limitations of overly bureaucratic administrative 
chains that ultimately invalidate the purpose of medical research, that is, to do research.  
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In all of our experiments, prior to tissue collection, we perfused animals transcardially to 
remove all blood from their blood vessels. The rationale for this procedure was to 
prevent any spirochetes that may have been circulating in the blood, from producing a 
false positive in any of the CNS tissues during culture. Likewise, we wanted to prevent 
leukocytes that were circulating in the blood from giving us the false impression that 
they were in the brain or dura. We also perfused the animals prior to performing 
immunostaining in the dura. We think that this approach was conservative, rational, and 
justified for the purpose of cell culture, and flow cytometry, but it may have been a 
disadvantage for immunostaining. It is possible that more borrelia may have been 
adhering to blood vessels in the dura, and that the sheer forces produced by perfusions 
may have displaced spirochetes that would have otherwise been detectable with 
immunostaining. Moving forward, we will probably not perfuse mice prior to 
immunostaining, so we can get a better idea of whether perfusions underestimate the 
number of spirochetes in the CNS.  
 
Finally, with respect to isolating leukocytes from the brain, we used Percoll gradients to 
separate leukocytes from brain myelin, based on the differences in their respective 
densities. Overall this approach is effective, but relatively inefficient, as many 
leukocytes can be lost in the process, and sometimes there are too few leukocytes 
isolated to obtain the subsets of interest. A better approach would be to use one of many 
cell sorting technologies to isolate leukocytes based on the expression of common 
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leukocyte markers, such as CD45. Had we used this approach, we may have seen less 
variability in our flow cytometric data (Figure 3.4-Figure 3.8).  
 
4.6 Concluding Thoughts and Future Directions 
We have demonstrated that in C3H/HeN mice, intradermal infection with Bb 297 results 
in persistent infection in the meninges, alterations in B cell and T cell populations in the 
CNS, and behavioral deficits related to nociception, motor function and mobility. The 
observations that we made occurred most notably at 45 dpi, suggesting that our novel 
approach may have established an appropriate mouse model for late-stage Bb infection, 
ultimately resulting in neurological LD. We expect that this model may be quite 
important in future investigations, as it may elucidate the underlying mechanisms that 
facilitate or set the stage for either disease remission and clearance, or persistent illness, 
as is characterized by the collective syndromes of RLA and/or PTLDS.  
 
Of the many important questions that remains, one of them is “what other behavioral 
deficits exist in these mice?” We are interested in answering this question, because the 
results of other behavioral tests may give us clues as to which regions of the CNS are 
most affected by Bb infection. For example, if we repeat NORT experiments using 
shorter and longer resting intervals between tests, we may be able to determine whether 
the perirhinal cortex or hippocampus are affected in our model of neurological LD. As 
we discussed above, the NOLT test and the Morris water maze are also behavioral tests 
of interest, as they relate to visuospatial and spatial memory/learning, respectively. Other 
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behavioral tests that may provide valuable information include the balance beam, tail 
flick test, elevated plus maze, forced swim test, and sociability test, as described in Table 
4.1. 
 
As we described earlier, it will be useful to repeat the immunoglobulin experiments in 
the brain, and in the dura, with higher n-values, because these experiments could give us 
reliable information about the quality and magnitude of the humoral response in the 
CNS, in response to infection. In the future, we would like to perform these experiments 
using IgG, and specific IgG subclasses that include IgG1-IgG4, as each subclass can 
provide information about the type of B cell that is producing antibody. We are also 
interested in probing for differences in IgM production, to determine whether the B1 B 
cells that we observed in our model play an active role in antibody production. 
Performing immunostaining or ELISA tests for other IgG isotypes such as IgA and IgE 
may also provide new information about the function(s) of secreted antibodies in 
neuroimmune responses. On a related note, B cell depletion therapies as could help us 
understand the respective contributions that B cells and T cells make to the behavioral 
phenotype that we observed during Bb infection. Finally, cytokine analyses of the brain 
and dura would guide us in understanding whether a particular cytokine profile is 
associated with neuroborreliosis. We expect that either a Th1 or a Th17 cytokine bias is 
likely, due to the growing body of evidence that these types of cytokines can be 
associated with neuropathologies.  
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We are especially interested in determining where in the brain compartment Bb may 
reside, and which mechanism(s) it uses to establish pathogenesis. As we described 
above, there are at least 9 possibilities that encompass how Bb may enter different 
compartments of the brain. It will be critical to utilize tissue culture, at early time points 
so we may determine when exactly after infection is Bb first detectable in the brain. 
Immunostaining and imagining will also provide important information about 
anatomical location(s) that Bb has a tropism(s) for. Our expectation is that Bb enters the 
CSF from the blood via the CP, resulting in persistent infection and inflammation in the 
brain. Determining the specific mechanisms that Bb utilizes to subvert the BBB and/or 
the blood-CSF barrier could provide new insights about how to target and prevent Bb 
from establishing neurological infection.  
 
It will also be important to know whether our neurological LD mouse model could 
model post-infectious complications of LD, such as RLA or PTLDS. An approach that 
we are interested in, is determining whether the current “standard of care” antibiotic 
therapy with oral doxycycline, or intravenous ceftriaxone has any effect on Bb infection 
burden in the CNS, alterations in leukocyte populations in the CNS, or behavioral 
deficits. If we were to observe that antibiotic treatment did not effectively reverse the 
alterations that are associated with late-stage Bb infection, our mouse model would 
likely be appropriate for modeling RLA and/or PTLDS. These are particularly important 
questions, because answering them will help us to determine whether the current 
standards of care really are the best possible modalities of treatment. For example, if we 
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were to observe that none of the mice recovered with the current antibiotic treatment 
guidelines, we would be justified in trying other antibiotic therapies to determine 
efficacy of treatment for optimal outcomes. Alternatively, if we 
observed that only some mice recovered, mechanistic studies to explain these 
phenomena would be warranted, and could potentially explain why only some people 
develop post-infectious complications of LD, and/or other diseases.  
 
Our novel mouse model of neurological LD brings to light many other questions that 
could provide valuable insights about the relationship between the Bb spirochete, and its 
host(s). Other subjects of interest include determining what effect immunogenetics may 
have on the outcome of Bb infection, whether the timing of antibiotic therapy affects 
disease outcome, and whether sex differences may play a role in disease progression or 
pathophysiology.  
 
It appears that by answering a few simple questions about Bb infection, we have found 
ourselves surrounded by many new questions of greater depth, and an array of 
possibilities. It truly is an exciting time to be in science.  
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Table 4.1 Additional behavioral tests. Summary of additional behavioral tests of interest in mice with 
neuroborreliosis 
Behavioral Test NOLT
Morriz water 
maze
Balance beam Tail flick
Elevated plus 
maze
Forced swim
Sociability 
test
Parameter Tested
Visuospatial 
memory/learning
Spatial 
memory/learning
Motor 
coordination
Pain 
tolerance
Anxiety
Anxiety / 
depression
Social 
preference
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